A - Z List of Registered Resources

This is a list of all the registered resources in the Directory. Scroll through the list or use the filter box to restrict the resources displayed. If you would like to search for specific collections or capabilities based on additional criteria (such as disease), visit our Directory home page.



Name County Description
Add-Aspirin Translational Samples Middlesex Collection of whole blood samples for plasma and DNA extraction and formulin-fixed paraffin-embedded (FFPE) tumour samples
Apheresis MNC Collection North Lanarkshire A cell bank of allogeneic γδ T cells required to ensure that an adequate supply of γδ T cells is available for research and development purposes as well as to conduct future clinical trials using γδ T cells (unmodified or modified) as IMP.
Archival gastro-intestinal tissue, blood, saliva and urine collection Lancashire Tissue bank contains paraffin blocks, a limited number of frozen tissue samples, frozen buffy coat, plasma and serum, frozen urine and frozen saliva.
Archival genito-urinary tissue, blood, urine and saliva collection Lancashire Archival genito-urinary tissue, blood, urine and saliva collection
Archival nervous system tissue and blood collection Lancashire Archival nervous system tissue and blood collection
Arden Tissue Bank Warwickshire Arden Tissue Bank operates under a Human Tissue Authority post mortem licence within a district general hospital. The biobank has generic ethical approval, and is able to collect tissues prospectively across a wide range of tissue types. In addition the biobank has access to the full pathological archive across three hospital sites. The cellular pathology archive is searchable by SNOMED coding for selection of specific conditions of interest. The cellular pathology archive alone totals almost 2 million blocks, with full patient data available from 2005 including pathology reports.
ARISTOTLE Trial Middlesex ARISTOTLE is a multicentre, phase III, randomised trial comparing standard neoadjuvant chemoradiotherapy (CRT) of oral capecitabine and radiotherapy versus standard CRT with the addition of irinotecan. 600 patients with MRI defined locally advanced, non-metastatic rectal cancer will be allocated in a 1:1 ratio to the two treatment arms. Samples collected for translational research as part of the trial: (i) archival tumour tissue blocks (from diagnostic biopsy), (ii) tumour tissue blocks and normal mucosal tissue from tumour resection (post CRT), (iii) plasma for circulating tumour DNA (ctDNA), (iv) buffy coat for germline DNA.
AstraZeneca Cambridgeshire AstraZeneca has a global biobank network storing human biological samples from AZ sponsored clinical trials, collaborations and also procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity, Neuroscience. There are over 1 million samples logged in the AstraZeneca Biobank Application (ABBA). Work needs to be done to identify which specific sample sets can be shared (both from closed clinical trials and from those that were commercially acquired), by establishing those that have the appropriate consent level and data available and to get the necessary approvals in place for to access these samples.
Avon Longitudinal Study of Parents and Children (ALSPAC) Bristol The Avon Longitudinal Study of Parents and Children (ALSPAC) is a longitudinal cohort study which has been charting the health of 14,500 families in the Bristol area since the early 1990s in order to improve the health of future generations. The study is also known as the Children of the 90s study. Mothers were recruited during pregnancy. The children born in 1991 and 1992 (known as ALSPAC-G1) and their mothers and fathers (G0) have been followed since. A large amount of phenotypic and environmental exposure data has been collected via questionnaires, research clinics and record linkage. The study website contains details of all the data that is available through a searchable data dictionary. Many of the original participants are now becoming parents and we are recruiting the next generation of children (ALSPAC-G2). Therefore ALSPAC is able to make a completely unique contribution to health science, by being able to understand how health, well-being and disease are passed through families. Samples have been collected throughout the participants lives and include DNA, lymphoblastoid cell lines, blood, urine, saliva, placentas, hair, nails and milk teeth. A large amount of omics data has been generated from samples including genetic, epigenetic and metabolomic data. The samples and data form a resource for the scientific community for projects which comply with our access conditions as outlined in our access policy. This can be found on our study website. All data generated from samples must be returned to ALSPAC for inclusion in the data resource and will be made available to other researchers. Study participants can be recalled for specific sample and/or data collection exercises eg for recall by genotype, phenotype or exposure studies. Such studies will be designed on a case by case basis and will be subject to appropriate ethical approval. Please contact the laboratory (email addresses in contact section) to discuss sample requirements.
Baby Bio Bank Middlesex The Baby Bio Bank is a collection of over 50,000 biological samples and medical data collected fromover 2,500 pregnancies affected by recurrent miscarriage, preterm birth, intrauterine growth restriction and pre-eclampsia. We have also collected samples from pregnancies complicated with other medical conditions such as Diabetes, high BMI, hypertension, IVF, twin and a cohort of samples from uncomplicated pregnanciess. We hold DNA, RNA, serum, plasma and whole blood from both parents and urine from the mother. From the baby we hold cord blood, cord, placental tissues and membranes, DNA and placental RNA. The samples are avaliable for research into pregnancy complications.
Barts Bioresourse Middlesex The purpose of the Bart’s Bioresource was to establish a repository of generic consented patients clinically managed by Cardiac Services at Bart’s Health NHS Trust. In addition to this the consent includes the donation of human blood, tissue donation (e.g. atrial appendage or pulmonary vein tissue) for the purpose of establishing a biobank of samples for use in cardiac disease research. The patients are informed that “The purpose of the Bart’s Bioresource is to allow research into diseases of the heart and circulation (cardiovascular research). The Bart’s Bioresource is supported by the National Institute for Health Research, which is part of the National Health Service (NHS). The Bart’s Bioresource will be very valuable because it will help us to find new ways of identifying, treating and preventing diseases of the heart and circulation.”
Barts Cancer Institute Breast Tissue Bank Middlesex This ground breaking initiative will see the Barts Cancer Institute and 4 other centres around the country working together as one national resource, to house the multi-million pound Breast Cancer Now Tissue Bank. Professor Louise Jones and a dedicated team head up the Tissue bank in the Barts Cancer Institute. The tissue bank includes a dedicated cell culture team, and has just established the Metastatic Bank including a Rapid Autopsy Programme. In the coming years we will see the benefits to people with breast cancer, as research using tissues from the Bank will lead to new treatments which have the potential to save the lives of many thousands of people with this disease.
Barts CTU Middlesex We conduct research into the prevention of cancer with particular focus on preventive therapy and screening. We are involved in clinical trials and epidemiology.
Barts Gynae Tissue Bank Middlesex The purpose of the Barts Gynae Tissue Bank is to collect, store and share high quality tissue for translational research into gynaecological cancers. We collect gynaecological tissues, ascites, blood and urine that have been obtained during standard diagnostic and therapeutic procedures and are surplus to pathological diagnostic requirements. Tissues are collected from both primary and metastatic gynaecological cancer as well as from non-malignant tissues obtained in the course of standard investigation and treatment. The Barts Gynae Tissue Bank wishes to share the collection with academic researchers undertaking high quality research.
Barts Pancreas Tissue Bank Middlesex Pancreatic diseases can be very difficult to diagnose and monitor because of the location of the pancreas deep within the abdomen. Also, with the current range of tests it may not be possible (in some cases) to tell the difference between pancreatitis (inflammation of the pancreas) and other conditions such as cancer of the pancreas without surgery and direct biopsy of tissues from this organ. This project is aimed to create a research tissue bank (explained below), specifically for pancreatic diseases. It will help researchers conduct a range of investigations in the near future. Thus this research project aims to develop new diagnostic tests as well as treatments for patients with pancreatic disease.
BEST3 Trial Cambridgeshire The BEST3 Trial is a Cluster Randomised Controlled Trial comparing the Cytosponge™-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care. The following types of the samples are collected as part of the Trial methodology: • Cytosponge™ samples • Saliva samples (TFF3-positive Cytosponge™ cases) • Endoscopic biopsy samples including gastric cardia and clinically-indicated oesophageal biopsies Cytosponge™ and endoscopic biopsy samples will be further processed into FFPE blocks and tissue sections.
Biliary Tract Cancer Virtual Tissue Bank London We plan to create a national virtual tissue bank of tissue samples from Biliary Tract Cancer patients who have participated in a clinical trial, and their associated prospectively collected clinical trial data, for high quality, peer reviewed and ethically approved research. Samples will be collected and stored in three separate Biobanks: 1) UCL/UCLH Biobank for Studying Health and Disease 2) Manchester Cancer Research Centre (MCRC) Biobank 3) Southampton Biobank Central Coordination of the BTC VTB will be conducted by CR UK & UCL Cancer Trials Centre (UCL CTC). To gain access to the samples Researchers will be required to submit to the BTC VTB Scientific Review Committee (SRC), via the UKCRC directory in the first instance. If approved by the SRC it will then be submitted to the Access Committee for each relevant Biobank. Samples will be collected from the following trials: • ABC-01 • ABC-02 • ABC-03 • ABC-04 • ABC-07 • Photostent-02 • BILCAP • ACTICCA-1
Biobank for patients with retinal degenerations & dystrophies Northumberland Outer retinal disease is the most common cause of blindness in the UK. It can be caused by a variety of single gene defects, including conditions such as retinitis pigmentosa which often result in early onset blindness in childhood, whilst the risk of age related macular degeneration is caused by a variety of complex multigene defects causing visual loss in later life. Treatments are evolving for both diseases but the underlying pathogenesis and treatment of these diseases remains elusive. We have formed the biobank as a repository of fibroblasts (from skin and hair samples) from patients with a variety of retinal diseases that could then be used with induced pluripotent stem cell technology to investigate causes and new treatments for these conditions.
BioDock Nottinghamshire Proud to be an industry leader in cryogenic storage. Our state-of-the-art facilities are based in the UK and Switzerland. Storing over 500,000 samples from over 70 different countries
Biology of the Human Uterus in Pregnancy and Disease Tissue Bank Cambridgeshire This tissue bank was established to support the research of members of the Centre for Trophoblast Research at the University of Cambridge into maternal-fetal interactions during pregnancy. Because of the limited number of samples available it is not possible to supply tissues to external researchers unless in the context of a collaborative project with a member of the Centre.
Bloodwise Childhood Leukaemia Cell Bank North Yorkshire The Bloodwise Childhood Leukaemia Cell Bank is a national collection of samples from children and young people with paediatric haematological malignancies. It is very well annotated with demographic, clinical and genetic features. This annotation enables identification and curation of very rare subgroups. There is a range of sample types including viable cells and DNA from bone marrow, plasma and CSF supporting many different types of project. The Bank is open to international as well as UK-based researchers where at least one of the investigators is based at a UK university or NHS institution. Applications are reviewed rapidly by an independent review panel. Our team can give help and advice at all stages of the application from initial enquiry to dispatch of samples. The Bank also holds a collection of HLA typed cord blood which are subject to the same review process.
BOXIT Surrey A randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder
BRAIN UK Hampshire BRAIN UK is a virtual brain bank which provides access to tissue already available in NHS archives as well as the provision of generic ethics. The BRAIN UK network includes 23 of 24 Neuropathology Centres across the UK.
BRASH Brain Tumour Bank South West, Bristol Bristol The aim of the brain tumour bank is to provide researchers with access to rare tumour tissue from the brain and spinal cord (which is surplus to diagnostic needs).The brain tumour bank has the approval of the National Research Ethics Service and is held under the Human Tissue Authority licence at North Bristol Trust. The bank is supported and regulated by Research and Innovation, North Bristol Trust.
Bristol Biobank Gloucestershire The Bristol Biobank (funded by the David Telling Charitable Trust with stakeholders from the University of Bristol and University Hospitals NHS Foundation Trust) stores samples collected from patients and healthy volunteers for use in biomedical research. Researchers in Bristol and beyond can apply to use these samples in their research. The collection of a wide range of samples will provide a platform for research into complex conditions. Researchers may request to deposit samples into the Biobank following the end of a NHS Research Ethics Committee approved study. Consent must have been taken using study specific documentation for the storage and use of these samples in research beyond the study. The Bristol Biobank team will also be happy to receive applications to deposit samples for specific projects you wish to set-up using Biobank permissions and documentation. The Bristol Biobank is licensed by the Human Tissue Authority (licence 12512) to store human tissue for research and has ethics approval from Wales Research Ethics Committee 3 as a research tissue bank to collect and issue biomaterials for biomedical research across a range of therapeutic areas.
Bristol Dental School Saliva Bank Bristol Whole human saliva is collected from donors at the Bristol Dental School at the University of Bristol.
Cambridge Blood and Stem Cell Biobank Cambridgeshire Cambridge Blood and Stem Cell Biobank collects and curates blood and blood-product derived samples from normal individuals and patients with blood and related malignancies, with particular emphasis on accessibility to purified tumour and stem cell populations from these samples. Set up in 2009, by 2016 the bank already contains over 12,000 samples, 70% from patients enrolled on research studies and clinical trials, and the remainder from cord blood donors. We specialise in bespoke fresh specimen collections for research into clonal blood cell disorders, autoimmune disorders and normal blood cell development.
Cam-UroOnc Biorepository Cambridgeshire The primary role of the CamUro-Onc is to consent, collect, log and store frozen tumour/normal tissues, blood and urine for use in approved research projects. The bank has been in operation since 2003 and now has an extensive collection of biosamples from urological diseases. Type of samples collected; - Fresh frozen and paraffin wax embedded tumour/normal tissue (where possible) from kidney, bladder and prostate. - Matching blood and urine samples. - Blood and urine samples collected as part of several research projects. These samples have been collected as part of various ethically approved research studies. The CamUro-Oncology Biobank is part of the Cambridge site of the ProMPT NCRI Prostate Cancer Collaborative. ProMPT provides infrastructure to take forward translational research in prostate cancer including the establishment of biorepositories and tissue collections together with epidemiological and clinical information. DIAMOND Study-(Discovery and Analysis of novel biomarkers in Urological diseases)- Collection of initial and sequential samples from subjects with benign and cancerous urological diseases.
Cancer Group CTR Cardiff trials Cardiff Centre for Trials Research Cardiff University. Trial sample collections
Cancer Tissue Bank Middlesex Controlling metastasis is an essential requirement for cancer management. The current model systems pay scant attention to human biology due to scarcity of evaluable patient samples. We propose an expansion of the tissue banks at the Barts Cancer Institute to include the collection of metastasis from a variety of primary tumours as well as distinct metastatic sites for use in laboratory research. This will facilitate identification targets to control tumour spread and develop novel biomarkers.
CANDAS London The Clinical Neurological Disease Biobank and Neurogenetics Research Study (CANDAS) bank is a clinical and biological database which will record the disease phenotype and facilitate the identification of genetic factors that: i.) predispose to neurologic disease; ii.) modulate the disease phenotype, leading to clinical differences and/or variation in drug responsiveness; and iii.) are responsible for rarer forms of Mendelian disease. We collect and store DNA samples, fibroblast cell lines, induced pluripotent cell lines and whole blood to enable this research.
Cardamon Clinical Trial Samples London Samples taken as part of the Cardamon clinical trial
Cardiff School of Dentistry Tooth Bank Cardiff Collection of both deciduous and permanent teeth. Collection of fresh teeth for extraction of pulpal cells can be arranged.
Cardiff University Biobank Cardiff The Cardiff University Biobank is a centralised biobanking facility sited at the University Hospital of Wales. We offer high quality human biosamples for research undertaken for patient and public benefit to academic and commercial organisations. We have established collections from a number of different disease areas and welcome approaches to initiate new collections not already established within the facility. The biobank also welcome applications to deposit samples from completed research projects or clinical trails.
CASPS: A Phase II trial of Cediranib in ASPS patients Surrey CASPS is a two-arm, randomised, double-blind, placebo-controlled, Phase II trial of cediranib in ASPS patients. The primary objective is to evaluate the efficacy of cediranib by measuring the percentage change in the sum of target marker lesion diameters from randomisation to week 24 compared to placebo. Secondary objectives include: progression-free survival, overall survival and safety and tolerability of cediranib in ASPS patients. Tissue markers of tumour response, circulating markers of angiogenesis, and changes in circulating endothelial cells/precursor cells in response to cediranib will be explored. Thirty six patients with progressive, metastatic, histologically confirmed ASPS will be recruited. Patients will be randomised to 24 weeks of blinded cediranib or placebo, after which treatment will be unblinded and all patients offered open-label cediranib until objective disease progression, or death if sooner.
Central England Haemato-oncology and oncology Research Biobank (CEHRB) West Midlands The Central England Haemato-Oncology and oncology Research BioBank (CEHRB) predominantly stores excess material from haemato-oncology and oncology samples referred for diagnostic testing and disease monitoring at the West Midlands Regional Genetics Laboratory (WMRGL). Haemato-oncology samples are stored at presentation and throughout the disease course, including at remission and relapse. In addition CEHRB stores haemato-oncology and oncology samples which are specifically taken for the biobank, usually in response to a specific project. CEHRB is housed within the WMRGL which is accredited by United Kingdom Accreditation Services to ISO15189:2012. The WMRGL serves a population of about 6 million and is the largest UK NHS genetics lab. Due to the large patient population CEHRB is able to collate sufficient research material from all classifications of neoplastic haematological disorders including those that are rare.
CEPA Biobank Newcastle Northumberland The CEPA Biobank can provide samples to both Researchers and Commercial companies on a cost recovery basis. We mainly work on a prospective collection basis, providing samples to specified instructions.
Children's Cancer and Leukaemia Group (CCLG) Tissue Bank Leicestershire National collection of childhood, teenagers and young adults solid tumour samples and lymphomas in the UK. Samples are centrally stored at the Central Bank, Newcastle University.
CMFT Biobank Lancashire Our biobank is a resource for health research available to all bona-fide researchers via our application process. We hold a large collection of human biological samples with associated clinical information. All human biological samples collected by The Biobank have full ethical approval, and is handled within the conditions of the ethical approval gained, in accordance with the requirements of the Human Tissue Act 2004 and under the governance of the Human Tissue Authority (HTA) Licence (#12552). The Biobank has been ethically approved as a research tissue bank by the NRES Committee North West – Haydock (Ref: 14/NW/1260). The Biobank is authorised to ethically approve biomedical research projects that fall within this governance structure. Researchers receiving samples from The Biobank are not required to have individual project based ethical approval from NRES. Tissue types Uterus (tumour, associated normal, control normal, benign conditions) Ovary (tumour, associated normal, control normal, benign conditions) Colon, ileum (tumour, associated normal, control normal, crohn’s disease, ulcerative colitis) Kidney (tumour, associated normal, control normal) Liver (tumour, associated normal, control normal) Prostate (tumour, associated normal) Thyroid, parathyroid (tumour, associated normal, benign conditions) Head & neck (tumour, associated normal, control normal) Sample types Fresh tissue in perfusion solution (medium of choice available 1hr post-surgical removal) Frozen tissue FFPE (formalin fixed paraffin embedded) tissue blocks Frozen or FFPE tissue sections mounted on glass slides Blood or tissue-derived DNA, RNA and protein Case-matched serum and plasma
CONFIRM Trial Hampshire CONFIRM is a double blind randomised phase III trial comparing nivolumab (anti‐PD‐1 antibody) monotherapy versus placebo for one year. The treatment allocation ratio is 2:1 (treatment: placebo).
Daisy Tumour Bank East Riding of Yorkshire The Daisy Tumour Bank (DTB) is creating various collections of human samples to share with researchers, thus providing a resource of fit for purpose biological material to facilitate ethically approved cancer research. The DTB is collecting human tissue and blood samples from cancer patients within Hull University Teaching Hospitals NHS Trust. The DTB is a newly established biobank which is in the accrual process, therefore samples and data are not accessible to researchers at this time.
DARWIN1 Trial London Blood and tissue from lung cancer patients
Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWIN II) London A phase II, multi-centre, non-randomised, molecularly stratified trial for NSCLC patients to study tumour heterogeneity using genomic analysis
DOC-MEK Oxfordshire A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma. The aim of this study was to assess the efficacy and safety of selumetinib combined with docetaxel as first-line treatment in patients with wild-type BRAF advanced melanoma.
Donate For Research Initiative (DRI) Cardiff Focusing on the procurement and supply of Fresh Biological Human samples and prospective studies. Open collaborations with other research Tissue Banks to facilitate multidisciplinary research and coordinated collections to benefit life science researchers.
Dr Karen Sisley South Yorkshire Eye tumours
Early Pregnancy Tissue Collection Lancashire Embryonic and fetal tissue (including placenta) collected from voluntary terminations of pregnancy
eLIXIR - Early Life Data Cross-Linkage in Research London The embryo, fetus and newborn child are very sensitive to external influences during development. These can arise from problems with the mother's health, her lifestyle, her physical environment, medication, the placenta not working properly, complications during birth, or as consequence of being born too early. Adversity in these periods of developmental vulnerability can have persistent effects on the long-term health of the child, including physical and mental health disorders. We also know that if a mother has complications in pregnancy, that she herself may suffer from increased risk of ill-heath in later life, for example cardiovascular disease, diabetes or mental health problems. eLIXIR is a prospective collection of blood samples from routine antenatal and neontal appointments and is due to begin collecting in 2018.
EMR Arthritis Biobank London The EMR Arthritis Biobank provides a unique bio and data resource, with biological samples (tissue and fluids) and stringent clinical data collected from patients recruited to our various clinical trials/studies including PEAC, R4-RA, STRAP/STRAP-EU, Therapist, IRMA, PSABRE, BHSLE & TRACTISS (completed and on-going studies). Patients recruited to our studies have rheumatic conditions such as Rheumatoid, Psoriatic and Undifferentiated Arthritis, as well as auto-immune diseases such as Lupus and Sjogren's syndrome.
EPHOS-B Trial Surrey Effect of Perioperative AntiHER-2 Therapy on Early Breast Cancer Study – Biological Phase (EPHOS-B). The EPHOS-B trial is a multicentre, three group, randomised controlled trial conducted in two parts. Part 1 (protocol versions 1 to 4): HER2+ patients were allocated in a 1:2:2 ratio to control, perioperative trastuzumab only or perioperative lapatinib only. This part of the trial will be superseded by Part 2 following the approval of amendment 5 by West Midlands - Edgbaston NRES Committee on 15/05/2013 and subsequently in each centre. Part 2 (Implemented from protocol version 5): HER2+ patients are allocated in a 1:1:2 ratio to control, perioperative trastuzumab only or the combination of lapatinib and trastuzumab. This part is now active.
Epilepsy Society Brain and Tissue Bank Middlesex The Epilepsy Society Brain and Tissue Bank is a recently established tissue bank at the Institute of Neurology, which has ethical approval and is supported by the Epilepsy Society. It is located within UCL Institute of Neurology in the Department of Neuropathology and is governed by a committee including members of the Department of Clinical and Experimental Epilepsy, the Epilepsy Society as well as SUDEP Action. The collection comprises consented tissue samples from patients who have undergone epilepsy surgery, mainly at the National Hospital for Neurology and Neurosurgery. In addition the tissue bank archives whole brain samples from patients with epilepsy and particularly epilepsy-related deaths, such as sudden and unexpected death in epilepsy (SUDEP). We have a donor registry for people who have epilepsy, seizures or who are healthy, without seizures, who wish to donate brain tissue following death.
ESPAC-TPlus Lancashire To centralise tissue and other clinical samples from the ESPAC studies, and make them available for future studies. Storage of the samples is designed to facilitate specific studies on response to chemotherapeutics. These separate studies will be subject to individual ethics applications. If successful they will allow subgroups of patients to be identified who will be predicted to benefit from particular chemotherapeutic regimens, improving survival for individual patients and facilitating clinical trials.
Ethical Tissue - University of Bradford West Yorkshire Ethical Tissue is a research tissue bank, licensed by the Human Tissue Authority (HTA); to collect, store and supply a wide range of human tissue, cells and fluids to biomedical research groups in academia and industry. Also includes tissue donated after death.
EXCEED study Leicestershire EXCEED is a longitudinal population-based cohort which facilitates investigation of genetic, environmental and lifestyle-related determinants of a broad range of diseases and of multiple morbidity through data collected at baseline and via electronic healthcare record linkage. * Recruitment has taken place in Leicester, Leicestershire and Rutland since 2013 and is ongoing, with approximately 10,000 participants aged 30-69 to date. The population of Leicester is diverse and additional recruitment from the local South Asian community is ongoing. * Participants have consented to follow-up for up to 25 years through electronic health records and additional bespoke data collection is planned. * Data available includes baseline demographics, anthropometry, spirometry and lifestyle factors (smoking and alcohol use), and longitudinal health information from primary care records, with additional linkage to other EHR datasets planned. Patients have consented to be contacted for recall-by-genotype and recall-by-phenotype sub-studies, providing an important resource for precision medicine research. * We welcome requests for collaboration and data access by contacting the study management team via exceed@le.ac.uk.
Extracted teeth Biobank Cheshire Samples and data are donated on the basis that they will be used for the benefit of other patients and for society in general. The bank plans to maximise benefits to society by using the extracted teeth to develop improved methods of detecting tooth decay. The caries detection rate of different methods can then be compared with the "ground truth". which uses an histological examination of the teeth. We propose to publicise the existence of the bank on
Generation Scotland Midlothian A collaboration between the Universities of Edinburgh, Glasgow, Dundee and Aberdeen, and NHS Scotland, to provide resources for genetic and medical research.
Genome Damage and Stability Centre-Research Tissue Bank East Sussex The Genome Damage and Stability Centre’s (GDSC) Cell bank was established in 1975. It houses material (skin biopsies, fibroblast and lymphoblastoid cell lines) collected from individuals, with various genomic instability disorders, with the aim of understanding more about the molecular basis underlying these disorders and providing data which aids the diagnosis and treatment of affected patients.
GlaxoSmithKline Research Tissue Bank Hertfordshire GlaxoSmithKline R&D has a global biobank network storing human biological samples from GSK R&D sponsored clinical trials, collaborations and commercially procured samples. These samples span the following main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, Respiratory, Inflammation and AutoImmunity. There are several million samples logged in the GlaxoSmithKline R&D sample tracking systems. Work needs to be done to identify which specific sample sets can be shared (both from closed clinical trials and from those that were commercially acquired), by establishing those that have the appropriate consent level and data available and to get the necessary approvals in place for access these samples.
GoDARTS Angus The GoDARTS Study has stored specimens of whole blood, serum, urine and DNA from consented patients with type 2 diabetes and matching controls (non diabetics) resident in the Tayside region of Scotland. Additionally GWAS data on ~10,000 cases is available. This resource is available to researchers worldwide to help define genetic factors related to diabetes including susceptibility, complications and response to treatment.
GoSHARE (Genetics of the Scottish Health Research Register) Angus The Scottish Health Research Register SHARE adopts an approach which asks the public to consent to their data held in NHS databases to be used to determine their suitability for research projects. Additionally participants can consent for spare blood, left after routine venepuncture to be stored for future research studies. This has been implemented in tayside and Grampian with over 50,000 blood samples intercepted by March 2017. Anyone over the age of 11 years in Scotland can participate. Participants are approached through a range of methods including directly at out-patient clinics and GP practices, leaflets with hospital letters and personal email from employers. SHARE has recruited around 150,000 people, with over 95% of all individuals providing consent for the use of spare blood. SHARE has demonstrated that it can quickly and efficiently recruit to studies. In addition it can be used to administer questionnaire studies by email and recruit to patient and public involvement groups. SHARE continues to steadily recruit with the ambition of eventually achieving 1,000,000 people in Scotland. We are steadily extending the datasets we use for identifying participants. We are adding a mobile APP which will facilitate dissemination about research and allow the collection of physiological and activity data if desired. We anticipate SHARE will soon become the main source of health research recruitment in Scotland. Cohort description paper: PMID: 28148535
HaemBio Biobank Oxfordshire Biobanking Biological Samples for Research in Haematological Malignancies
HALT Surrey HALT is a phase II/III, multicentre, randomised controlled trial in patients with advanced non-small cell lung cancer (NSCLC). Patients will have a defined, actionable mutation responding to targeted tyrosine kinase inhibitor (TKI) therapy and 3 or fewer sites of oligoprogressive disease, which will have developed after becoming resistant to targeted TKI treatment. 110 patients will be randomised to phase II of HALT with participants allocated to receive Stereotactic Body Radiotherapy (SBRT;73 patients) or not (37 patients). All patients will continue TKI therapy. The phase II study aims to evaluate if the addition of SBRT to treat limited (≤ 3) sites of oligoprogressive disease with continuation of current TKI therapy improves progression-free survival outcomes in patients compared with continuation of TKI alone. The focus of the translational research will be on identifying clinically translatable biomarkers to identify patients who are likely to benefit from SBRT versus patients where transition to the next line of systemic therapy would be appropriate.
HCV Research UK Glasgow (City of) HCV Research UK is a UK-wide consortium established in 2011 to underpin research into hepatitis C (HCV). This was achieved by establishing a biorepository and clinical research database. The biorepository is housed in the MRC-University of Glasgow Centre for Virus Research, directed by Dr John McLauchlan and managed by Dr Sarah McDonald. Samples have been obtained from around 10,000 patients. Access to samples and data is governed by a Tissue and Data Access Committee (TDAC). These are reviewed for ethical and scientific merit by TDAC and a decision reached. Serum and plasma are obtained from all patients in the cohort. Buffy coats are also collected, and DNA can be extracted when required. Additionally, peripheral blood mononuclear cells (PBMCs) and PAXgene tubes are held for smaller cohorts of patients. The extensive clinical data collected complements the biorepository and allows selection of samples from patients with characteristics of interest. Sub-cohorts: • Serial samples from patients who were treated as part of the NHS England Early Access Program. • Yearly samples from cirrhotic patients (beginning 2015) • Spontaneous resolvers • Small paediatric cohort Clinical Data • Basic demographics incl place of birth and ethnicity • History of HCV infection including exposure to risk factors and dates • Date of diagnosis, date of first attendance at clinic • Co-morbidites and co-medications at time of enrolment • Liver disease status and how diagnosed • Treatment status at enrolment; • Social history including alcohol, cigarettes, cannabis; BMI • HCV RNA status, viral load and genotype/subtype • Historical data from the patients' notes regarding previous treatment episodes (dates, regimen, viral loads, outcome) and liver biopsies • Laboratory data including imaging and fibroscan; • New treatment episodes and changes in liver disease status are recorded over time, as are any newly developed co-morbidities. All data generated by researchers who access our biorepository must be returned into the database. Over time this will include host genetics, full length viral sequences, immunophenotyping and biomarker studies.
HPB Biobank Middlesex Prospectively collected fresh tissues from surgery. All patients fully consented. Snap frozen paired cancers and normal tissues. Stored in liquid nitrogen HCC Cholangiocarcinoma Liver mets Benign tumours Gallbladder cancer Pancreas and ampullary cancers 1010 samples currently in bank
Human Biomaterials Resource Centre Warwickshire The HBRC is an HTA-licensed biorepository dedicated to the collection of appropriately consented high quality human biomaterials, their processing, storage and distribution to biomedical researchers. The HBRC resides within the purpose-built Advanced Therapies Facility (ATF) within the College of Medical and Dental Sciences (CMDS) at the University of Birmingham (UoB). The ATF also houses both cell and gene therapy manufacturing units. Samples are collected, processed and stored (or released) from patients in a variety of disease settings in response to local demand and research strategies in order to facilitate existing research and enable future research areas to be developed. Samples may comprise adult or paediatric tissue which is waste, or surplus to diagnosis taken at the time of surgery or treatment, additional samples taken specifically for research purposes, material taken from patients enrolled in clinical trials, and control material. The HBRC works with local researchers and carries out bespoke tissue collections. All samples can be annotated with the appropriate clinical data which makes them scientifically useful. Although the HBRC is primarily a resource for local researchers within CMDS and local NHS Trusts, applications from other UK research groups and the commercial sector are also considered. The policy and procedures associated with the review of these applications, and the subsequent release of samples and associated data, are the same for both internal and external applicants. All samples and associated data are released for research in a fully anonymised form, and a Tissue Transfer Agreement ensures that they will only be used for the purposes approved at release and will not be transferred without written permission. In order to enhance the value of the HBRC collection, every attempt is made to secure the return of useful research data following the completion of research studies.
Human Developmental Biology Resource (HDBR) Northumberland The Human Developmental Biology Resource (HDBR) is an ongoing collection of human embryonic and fetal material ranging from 3 to 20 weeks of development. Material is available to researchers internationally following registration with the tissue bank. Jointly funded by the MRC and Wellcome Trust, the biobank has been operating since 1999 and is based at two centres: Institute of Genetic Medicine – Newcastle University and the Institute of Child Health – University College London. Tissues can be dissected to meet specific research needs and samples supplied fixed or frozen for histology or nucleic acid extraction, or the tissue can be collected into culture media to be used to establish cell lines. Material pre-sectioned to microscope slides is available for immunohistochemistry (IHC) or tissue in situ hybridisation studies (TISH) and stage, tissue specific RNA/DNA/cDNA can be requested. Our In House Gene Expression Service will perform IHC or TISH experiments on behalf of registered users and provide them with high quality annotated images of results ready for publication.
HYWEL DDA BIOBANK Carmarthenshire This is a University Health Board Biobank initially concentrating on lung and breast material but will expand to other specialities in the future..
ICHTB Middlesex Human tissue bank holding samples in a variety of different formats at Imperial College London
ICON9 Trial London An international phase III randomised study to evaluate the efficacy of maintenance cediranib and olaparib combination therapy or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
IDRIS Trial London Phase III randomised study of immunomodulatory therapy in high risk solitary bone plasmacytoma. IDRIS is a randomised, open label, multicentre phase III study. The aim is to investigate whether the administration of adjuvant lenalidomide and dexamethasone following standard radiotherapy treatment for SBP prevents or prolongs the time to development of further plasmacytomas or progression to myeloma, or death (whichever comes first), in patients with high-risk disease compared with RT only. Patients are risk-stratified following registration into the trial. Risk stratification is based on BM immunophenotyping and SFLC ratio. All patients will receive standard local radiotherapy; this is not regarded as trial treatment and may be administered prior to study entry. - Patients with high-risk features will be randomised to receive adjuvant therapy in the form of lenalidomide and dexamethasone or no further treatment. - Patients without high-risk features will receive no further therapy and will be observed according to local practice. 140 patients: - 98 patients with high risk features to be randomised at a 1:1 ratio - 42 low risk patients for registration only
IMPORT HIGH trial blood samples Surrey Blood samples from patients with early stage breast cancer who received breast conserving surgery and appropriate systemic therapy and radiotherapy.
INCA Trial London INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy. 132 patients will be randomised to receive either IO-R-CVP or Gem-R-CVP. Samples collected for trial: 7ml EDTA blood sample taken at baseline; Formalin fixed paraffin embedded tumour block - both sent to HMDS, Leeds. Blood serum sample (4.9ml) taken at Baseline (between day -14 pre registration and day 1 pre-treatment), Cycle 1 day 3 (+/- 1 day), Cycle 1 day 8 (+/-1 day) and Cycle 2 day 1 (-1 day) to be sent to Cancer Research UK Manchester Institute, Macclesfield.
Infectious Diseases BioBank at King's College London Surrey Fractionated blood products from patients with HIV, hepatitis C viral infections and others with bacteraemias.
interNational Anaplastic Thyroid Cancer Tissue Bank (iNATT) Cardiff The primary objective is to establish an international anaplastic thyroid cancer tissue collection to facilitate research. Patients have the option to donate blood samples and clinical data. Research proposals will be accepted from academic and industry research parties from the UK and internationally. All research proposals will be submitted to the multidisciplinary iNATT Steering Committee for assessment. As the volume of tissue collected per patient is expected to be of small volume, by virtue of the specimen comprising core biopsy or fine needle aspirate material, research proposals will be prioritised according to the potential clinical benefits. Research proposals will require ethical approval and the relevant research and development permissions prior to commencement. ClinicalTrials.gov Identifier: NCT01774279
IoN Trial Middlesex IoN is a multicentre phase II/III asking is ablative radioiodine necessary for low risk differentiated thyroid cancer patients. 560 patients will be recruited and randomised 1:1 to receive radioiodine ablation or no ablation. Samples collected during trial: Stimulated Tg blood samples for patients taken at the treatment visit, 2 months post treatment, 6-9 months post treatment and every 6 months thereafter for 5 years.
King's Adult Liver Research Biobank London Biobank storing a collection of blood and blood fractions, tissue (fixed and frozen) and a variety of other tissue types from a variety of conditions of the Liver and Hepatobiliary tract, including the pancreas.
kings college Haemato -Oncology Tissue bank London The objective of our Tissue Bank is to serve as an international bioresource to facilitate basic and translational research into the aetiology, diagnosis and prognosis of blood cancers and to pursue this aim in a manner that complies with all laws, regulations and industry standards that apply to research tissue banking.Thus, our bank is rich in material from adult patients with pre-leukaemic and bone marrow failure disorders, including myelodysplastic syndromes, aplastic anaemias and paroxysmal nocturnal haemoglobinurea. The bank is also populated with material from patients with chronic and acute myeloid leukaemia, myeloma and chronic lymphocytic leukaemia.
King's Health Partners Cancer Biobank Surrey King's Health Partners Cancer Biobank collects blood, tissue and urine samples from patients with a range of cancer types who are referred to Guy's & St Thomas' NHS Trust. The Breast Biobank alone has been providing tumour samples with matching clinico-pathological data for research studies since the 1970's. Other tumour types including lung, head and neck, prostate, UGI, bladder, colorectal, lymphoma and MPD have been added since 2008. The Biobank is accessible to both academic groups and commercial companies.
King's Paediatric Liver Tissue Biobank London The paediatric liver tissue bank contains samples from children with rare liver diseases taken longitudinally.
LBIH Biobank Lancashire The LBIH Biobank has been specifically created to provide SMEs and academic researchers with high quality biosamples, data, and analytical services. We house a vast array of biosamples, both cancerous and non-cancerous, and have the ability to collect bespoke samples and data to suit the needs of researchers. We have access to a wide variety of samples types including, but not limited to, frozen tissue, fresh tissue, blood products, urine and FFPE blocks. The LBIH Biobank can further process these into a number of products such as DNA, frozen sections, and cryo-aliquots. In order to offer a ‘one-stop shop’ for research, we offer additional services such as IHC, next generation sequencing,TMA creation, and project management for studies and projects, to include storage of trial samples.
LCTU Post-Trial Tissue Bank Merseyside The collection consists of samples and data collected from individuals who have participated in clinical trials managed by the Liverpool Cancer Trials Unit (LCTU) and who have given informed consent for the use of their samples in translational research activity. The samples and data available fall under four core malignancy groups: •Hepato-pancreato-biliary (HPB) cancers •Uveal melanoma •Head and neck cancers •Breast cancer •Lung cancer Samples stored in the collection include, but are not limited to whole blood, cell pellets, tissue (tumour and healthy), plasma, peripheral blood mononuclear cells and urine. Samples will become part of the LCTU Post-Trial Tissue Bank upon completion of the intended primary translational objectives. Linked, anonymised data includes demographic, clinical and fully audit tracked laboratory data.
Leeds Breast Research Tissue Bank West Yorkshire The Leeds Breast Research Tissue Bank (LBRTB) was established in 2010 and collects malignant and normal breast tissue and associated samples from donors consented through the Leeds Teaching Hospitals Trust. The LBRTB is based in the Leeds Institute of Cancer and Pathology on the St. James's University Hospital site and is led by Professor Valerie Speirs. The LBRTB is a founder member of the Breast Cancer Now Tissue Bank (BCNTB), a ground-breaking multi-million pound initiative linking five centres around the country working together as one national resource. The BCNTB represents the UK's single largest unique collection of high quality breast tissue samples.
Leeds Dental Institute/School of Dentistry Leeds, Skeletal Tissues Bank West Yorkshire Tissue bank which stores teeth.
Leeds Multidisciplinary Research Tissue Bank West Yorkshire Background: The Leeds Biobanking and Sample Processing Lab (LBSPL) is based at St James’s University Hospital and is an important element in the Leeds Clinical Research Facility (LCRF). LBSPL is dedicated to providing a sample processing service for clinical trials, and for many biobanking activities within the University and Leeds Teaching Hospitals Trust. These currently include collections of tissue, and fluid samples such as blood and urine obtained from consented patients diagnosed with kidney, bladder, colorectal and ovarian cancer, brain tumours, and patients undergoing renal transplant. These are processed and stored in research tissue banks (Leeds Multidisciplinary RTB and Leeds NIHR Biomarker RTB) and used as a valuable resource for wider research activities. The Leeds Multidisciplinary Research Tissue Bank (RTB) was given favourable ethical opinion by the Leeds (East) Research Ethics Committee on 3rd March 2010 and renewed 5 yeasr later (Current REC ref: 15/YH/0080). Current situation: The LBSPL provides ongoing sample processing support to a variety of local or commercial clinical trials requiring samples to be collected for PK/PD endpoints or other associated translational studies. The Leeds Multidisciplinary RTB currently holds matched normal and malignant frozen renal tissue samples from ~600 patients with renal cancer, and plasma, serum, buffy coat and urine samples from ~800 renal cancer patients either prior to surgery/treatment or during treatment, for example with sunitinib. In addition, fluid samples have been collected from patients with benign urological conditions, healthy controls, patients prior to and following renal transplant A population-based TMA including tissue from ~300 RCC patients has also been established.From having solely a renal focus, the RTB has expanded to now also include frozen normal tissue samples, and frozen tissue and urine samples from >1,000 patients with bladder cancer, frozen tissue from patients with brain tumours and limited samples from patients with ovarian cancer or colorectal cancer (no new collections ongoing in these areas). The Leeds NIHR BioRTB has closed to recruitment and contains a bank of fluid samples from patients with liver disease, renal cancer and patient undergoing renal transplantation. These were collected as part of a multicentre initiative in the UK, together with associated clinical data, and are intended for use in biomarker validation studies. Sample processing and clinical data: Samples are processed according to the relevant quality controlled Standard Operating Procedures (SOPs) within Good Clinical Practice (GCLP) laboratories. The dedicated sample processing team of laboratory technicians, administrative staff and a Quality Assurance manager works together to ensure that all samples are handled, processed, stored and tracked to the highest standards. The samples are stored accordingly at the correct temperature (e.g. snap frozen tissue in liquid nitrogen, plasma, serum and buffy coats at -80oC). All freezers and liquid nitrogen dewars which hold patient samples are monitored using the Tutela system, a 24/7 web-based alert response temperature monitoring system. Full clinical data is being collected using CRFs. Follow-up data and data available later such as pathology results are obtained from the relevant hospital records/databases by trained personnel with appropriate access. We hope to move to more automated data linkage in the future through working with the Leeds Institute of Data Analytics. To find further information about collaborative access to these RTB samples please e-mail Roz Banks or Jo Brown at rtb@leeds.ac.uk.
Leeds NIHR Biomarker Research Tissue Bank West Yorkshire Background: The Leeds NIHR Biomarker Research Tissue Bank (RTB) is part of a National Institute for Health Research (NIHR) Programme Grants for Applied Research award, focused on biomarker evaluation in selected disease areas. The RTB was established for the multicentre collection and storage of samples from patients with liver diseases recruited within a randomised controlled trial (ELUCIDATE) of a biomarker panel, renal cancer patients and patients undergoing kidney transplant. The Leeds NIHR Biomarker RTB is jointly managed along with the Multidisciplinary RTB by the Joint RTB Management Committee. The Leeds NIHR Research Tissue Bank (RTB) was given favourable ethical opinion by the Leeds (East) Research Ethics Committee on 15th June 2010 (Current REC ref: 15/YH/0099). Sample collections: Over the duration of the programme, 2,116 participants were recruited in total with 5,976 samples. Sample collection has taken place in multiple centres in the UK. These comprise: • 847 patients with liver disease each with a single serum samples • 514 patients on the kidney transplant waiting list including 312 subsequently transplanted, with 3,806 samples, each sample including multiple aliquots of serum, plasma and urine • 706 patients with suspected renal cancer (200 longitudinal and 506 cross-sectional) with 1,132 samples, including multiple aliquots of serum, plasma, buffy coat and urine and an FFPE tissue block (frozen available in Leeds patients only) • 149 healthy volunteers with 191 samples, each sample including multiple aliquots of serum, plasma and urine All samples were collected according to SOPs and have been shipped from the participating sites and stored centrally in Leeds Biobanking and Sample Processing Facility. Associated clinical data has been collected using standard study-specific case report forms (CRFs), including long-term follow-up in many cases. Initially access to samples is prioritised for the needs of the Programme and investigators involved but additional collaborative access will then be possible. To find out further information please e-mail our Research Tissue Bank and Sample Processing Facility Manager, Pirkko-Liisa Muhonen at rtb@leeds.ac.uk.
Leicester Institute for Lung Health Research Tissue Bank Leicestershire Medical research is currently in an era in which thousands of genes, RNA molecules and proteins can be analysed in a single experiment, meaning that large numbers of potential molecular markers for disease are being identified. To validate and translate these biomarkers large series of tissue and other biosamples are required. The Leicester Institute for Lung Health (LILH) Research Tissue Bank (RTB) is intended to meet this need and to facilitate high quality research. The LILH RTB will support projects from all sections of the respiratory research community within Leicester, while remaining open to provision of tissues and samples to organisations outside Leicester. Researchers from academic, charitable and commercial organisations will be able to apply for access to banked tissue samples.
Liverpool Musculoskeletal Biobank Merseyside The Biobank aims to facilitate musculoskeletal research. To support primarily research in the University of Liverpool. It will also support other research partners both nationally and internationally. A variety of musculoskeletal tissues are collected prospectively from consented patients undergoing both elective and trauma orthopaedic surgery. Patients demographic and medical history is obtained as well as outcome and quality of life assessment scores. We are able to collect all orthopaedic surgery waste products e.g. cartilage, bone, synovium, synovial fluid, adipose tissue, ligaments, muscle, capsule, bone marrow and venous blood samples.
Liverpool University Biobank Merseyside The Liverpool University Biobank (LUB) is a multi-discipline biobank set up to consolidate the existing biobanks and tissue collections enabling a centralised approach to the human tissue management and integration of research within the University of Liverpool. It will incorporate retrospective collections of stored samples and prospective collection of new material.
Manchester Allergy, Respiratory and Thoracic Surgery (ManARTS) Biobank Cheshire Collection of samples from patients with respiratory and allergic diseases
Manchester Cancer Research Centre (MCRC) Biobank Greater Manchester Facilitating high quality cancer research by bringing a flexible and committed approach to ethical sample and data collection
Manchester Eye Tissue Repository Lancashire Repository of post mortem donor eye tissue collected after removal of the corneas for transplantation. It has been established particularly for research into macular disease (age-related macular degeneration), but other ocular tissues have been stored frozen including peripheral retina, sclera, lens, vitreous and optic nerve. Macular tissue has been stored frozen for immunohistochemistry (by embedding in OCT) and for biochemical studies. The donor tissue had been genotyped in relation to AMD risk. The Repository is funded by The Macular Society.
Manchester Skin Health Biobank Greater Manchester The MSHBiobank supports a varied programme of research involving skin and hair disorders. These include chemotherapy induced alopecia, inflammatory hair diseases, other alopecia’s (androgenic alopecia, Female patter hair loss) and skin research including wound healing, psoriasis and skin-related drug side effects. Research programs will aim to provide novel, publishable basic science data and contribute to patient well-being and treatment. Skin and hair samples are stored from patients who are asked to consent to collection of excess tissue left over from routine medical and cosmetic procedures.
MDSBio Oxfordshire Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and secondary disorders of haematopoiesis
MesobanK Cambridgeshire A global solution to a global problem. Mesobank is a Research Tissue Bank dedicated to the study of mesothelioma. We provide a comprehensive sample and data set from patients with mesothelioma and support biomedical research directly concerned with asbestos related disease undertaken within the UK, EEA, USA, Canada, Australia and New Zealand.
MOHS PHE Ebola Biobank Wiltshire During the Ebola outbreak in Sierra Leone in 2014-15, residual clinical specimens and accompanying data were collected from routine diagnostic testing in Public Health England (PHE) led laboratories. Approximately 10,000 samples of which 1,440 are positive for Ebola along with all the accompanying data have been transferred to PHE laboratories in the UK for curation by PHE. The Ministry of Health and Sanitation in Sierra Leone (MOHS) have retained ownership of the data and materials, and are working with PHE and other collaborators to conduct a series of research projects to inform future public health strategy relating to Ebola. The biobank is an open access resource for bona fide scientists undertaking health-related research that is in the public good. Scientists from the UK and overseas and from academia, government, charity and commercial companies can apply to the biobank. Samples will be released when the risk of them containing live virus has been eliminated using a validated inactivation procedure, which is discussed with the receiving researcher and currently has involved the use of a commercial RNA/DNA extraction kit. We plan to use X - ray radiation for inactivation at some point in the future.
Molecular Investigation of Haematopoietic Malignancy Study Middlesex This study focuses on procuring diagnostic, relapse, remission and progression specimens from Haemato-Oncology patients. This allows researchers to be able to investigate the development and progression of these malignancies in addition to studies into the unique microenvironment. The tissue is stored and equipment maintained to strict guidelines to ensure quality of specimens; the vast majority as single cell suspensions. Also available are samples from the Haemato-Oncology tissue bank which was established in the early 1970s. It is a huge resource containing specimens such as peripheral blood, bone marrow, serum and lymph node biopsies from primarily leukaemia and lymphoma patients. All samples are linked to the clinical outcome of these patients.
MRC Brain Banks Network Bristol The UK Brain Bank Network is an initiative, led by the MRC, to establish a coordinated national network of UK brain tissue resources (banks) for researchers to use. The banks store post-mortem brain and central nervous system (CNS) tissue donated by the public for diagnosis and research into disorders. Advances in understanding genetics and many of the molecules that define brain function mean that more and more research questions can be answered from human brain tissue.
Multiple Sclerosis and Parkinson's Tissue Bank London The Multiple Sclerosis and Parkinson’s Tissue Bank is a national collection of CNS tissue samples donated by individuals with multiple sclerosis (MS), Parkinson’s disease and related neuroinflammatory and neurodegenerative conditions. The Tissue Bank’s mission is to facilitate discoveries by making well-characterised human material of the highest quality readily available to the research community engaged in studies aimed at finding the cause and better treatments for MS and Parkinson’s. Furthermore, we aim to encourage the greater use of the material in scientific studies. It is by carrying out this work that the Tissue Bank fulfills the last, generous and selfless wishes of all those who have registered on the donor scheme and bequeathed their CNS tissues to research. The work of the Tissue Bank is supported by the Multiple Sclerosis Society and Parkinson’s UK in partnership with Imperial College London.
Myeloma XII clinical trial samples West Yorkshire Samples collected from myeloma patients at first relapse registered into the Myeloma XII trial, and sent to the following central labs: 1. Central immunology laboratory, University of Birmingham - peripheral clotted blood and urine collected at various timepoints throughout the trial; 2. Haematology Malignancy Diagnostic Service (HMDS) laboratory, St James's University Hospital, Leeds - bone marrow aspirate, collected at various timepoints throughout the trial; 3. Leeds Institute of Cancer and Pathology (LICAP), University of Leeds - peripheral blood, serum, and bone marrow aspirate collected at various timepoints throughout the trial.
National CJD Research & Surveillance Unit (NCJDRSU) BioResource Midlothian BioResource for human prion disorders including cerebrospinal fluid, blood, and urine.
National Diet and Nutrition Survey (NDNS) Cambridgeshire A National cross sectional population based survey. Additional data available including 4 day food diary, BP, biochemical analytes
National Unified Renal Translational Research Enterprise (NURTuRE) Cambridgeshire The NURTuRE project was devised to create a national kidney biobank as recommended in the UK Renal Research Strategy 2016. Strategic Aims: To work towards achieving this NURTuRE will: 1. Create a national Kidney Bio Bank for collection and storage of biological samples from 3,000 CKD patients and up > 800 NS patients, to provide a strategic resource for fundamental and translational research. 2. Develop and implement proactive UK protocol driven cohort studies in CKD and NS to investigate determinants of and risk factors for clinically important adverse outcomes. 3. Engage patient cohorts, with consent to approach for any future research study. NURTuRE Objectives: 1. The provision of comprehensive clinical and laboratory data from cohort studies. 2. The provision of high quality bio-samples with centralised storage/retrieval. 3. To carry out core biomarker analysis of biopsy specimens in biofluids of all patients recruited and parallel assessment. 4. Follow-up specimen collection. First patient recruitment – By 31 June 2017 CKD – baseline and 100 % follow up collections – over 2 years NS: baseline and 20% follow up – over 3 years. Healthy Volunteers - baseline
Newcastle Biobank, Newcastle University Tyne and Wear Newcastle Biobank is a research tissue bank within Newcastle University operating under Human Tissue Authority (HTA licence no. 12534). The biobank facilitates the collection of samples (excess to diagnostic requirement) from patients and volunteers for use in medical research. Applications are made to Newcastle Biobank to: (1) Establish a new sample collection for use in future unspecified research; (2) Access existing samples within the biobank. Newcastle Biobank also accepts legacy collections of samples from research projects with expiring ethical approvals. Newcastle Biobank holds many different types of samples, including solid tissues, cell suspensions such as ascitic fluid, blood samples, saliva, urine, buccal swabs etc. Both fresh frozen and fixed, embedded tissues are stored.
Newcastle MRC Centre Biobank for Rare and Neuromuscular Diseases Tyne and Wear The Newcastle MRC (Medical Research Council) Centre Biobank for Rare and Neuromuscular Disease is located at the International Centre for Life (Institute of Genetic Medicine, Newcastle University). The MRC Centre for Neuromuscular Diseases is a partnership between Newcastle University and the UCL Institute of Child Health and Institute of Neurology, and is one of the MRC's translational research centres in the UK. The Newcastle MRC Centre Biobank and the affiliated biobank located at the Institute of Child Health (UCL) in London, were established in 2008 and comprise one the five core activities of the MRC Centre for Neuromuscular Diseases aimed at supporting the translational program of the centre. The main objective of the biobank is to provide well characterized, high quality biomaterials such as myoblasts, fibroblasts, DNA, RNA, plasma, serum and urine of patients with neuromuscular disorders to researchers within the centre and the wider scientific community. Currently, the MRC Biobank has assembled a collection of more than 15,000 anonymised rare disease samples mostly derived from NMD patients. In 2010, the Biobank was recognised as an official member of EuroBioBank (http://www.eurobiobank.org/en/information/info_institut.htm) and has applied quality criteria and standard operation procedures in accordance with EuroBioBank protocols. Publication: MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. doi: 10.1016/j.nmd.2017.07.001
NHS Cord Blood Bank Gloucestershire We endeavor to minimise waste and process failure in the cord blood supply chain however, inevitably there is donated material that is surplus to clinical requirement or unsuitable for therapeutic use. We are in a unique position to supply this donated material for its own research and development, also to the NHS and to authorised external organisations for specific uses. Non Clinical Issue (NCI) operates on a cost recovery basis, We do not charge for material provided but recovers the costs of making this available. All income is used for the benefit of NHSBT
NHS Grampian Biorepository Aberdeenshire The Grampian Biorepository was developed to provide core facilities that could undertake research based around the collection, storage, analysis and distribution of human biological samples collected within NHS Grampian. The biorepository supports a range of tissue based projects. The main areas of research activity are translational research programs in colorectal cancer, lung cancer. In addition we have the following collections: orthopaedic tissues and liver samples, We have access to the Pathology Department archive consisting of patient identifiable paper documents, tissue blocks and glass slides containing in excess 1 million patient samples.
NHS Greater Glasgow & Clyde Bio-Repository Glasgow (City of) The NHS Greater Glasgow & Clyde Bio-repository is part of NHS Scotland NHS Research Scotland Infrastructure. There is a network of Bio-repository across Scotland designed to encourage use of tissue in research and boost availability of tissue across Scotland. Each Bio-repository node holds the responsibility for tissue governance for local and partner Health Boards with a main focus on facilitating access to surplus diagnostic and surgical tissue for use in research.
NICAM: Nilotinib treatment for c-KIT mutated advanced AMM Surrey Phase II single arm study evaluating the activity of nilotinib in rare c-KIT mutated acral and mucosal melanoma (AMM). Entry into the trial is a 2 step process. Patients presenting with AMM are first registered (Step 1) for screening including confirmation of c-KIT mutation status. Eligible patients who proceed to study entry (step 2) commence treatment with nilotinib 400 mgs twice daily for as long as they continue to benefit from treatment.
NIHR BioResource Cambridgeshire Panel of over 100,000 highly characterised healthy volunteers and patients with common and rare diseases, who are willing to be approached to participate in research studies investigating the links between genes, the environment, health and disease. Volunteers who join the NIHR BioResource donate their DNA via a blood or saliva sample which is used together with other information (e.g. gender, ethnicity, health records), to match them to specific research studies. Genotyping information via high density array is available for over half of the BioResource panel. Volunteers are free to choose which studies they would like to take part in, allowing the BioResource to provide researchers with groups of participants, tailor-made to the research study. Volunteers can currently be recruited from the thirteen existing BioResource centres located in Birmingham, Cambridge, Exeter, Leicester, London (at Barts Health, King’s College London Guys and St Thomas’, King’s College London South London and Maudsley, Moorfields and University College London), Leeds, Manchester, Newcastle and Southampton. Patient cohorts and research studies: The NIHR BioResource supports studies led by Academics, Clinicians and Industry partners including, but not exclusively, in the fields of autoimmune diseases, inflammatory bowel disease, cancer and cardiovascular diseases. As well as healthy volunteers, the NIHR BioResource has enrolled over 10,000 patients with Rare Diseases, and has cohorts of patients with cardiovascular diseases, mental health conditions, and Inflammatory Bowel Disease (the aim is to recruit 25,000 IBD patients). New patient cohorts are continuously being added. Industry partners may encounter a cost to access BioResource volunteers. A detailed cost for Industry-led studies through commercial agreements can be found at: https://bioresource.nihr.ac.uk/industry/industry-home/
NIHR Exeter Clinical Research Facility Devon NIHR Exeter Clinical Research Facility is a partnership between the University of Exeter Medical School and the Royal Devon and Exeter Foundation Trust. It is dedicated to facilitation of clinical and translational research. We have two main collections: the Peninsula Research Bank (PRB) and the Royal Devon and Exeter Tissue Bank (RDETB). The PRB has ethics to accept gifted samples from completed studies, and the bulk of the collection is from a dedicated biobank collection called EXTEND (the EXeter TEN thousanD), which aims to recruit one in ten of the local Exeter population. The majority (c. 75%) of our studies are local CI led, and we specialise mainly in diabetes, obesity and related pathologies. However, the majority of people within the EXTEND study are fit and well. The RDETB has overarching ethics to collect samples from diagnostic procedures with patients' consent. Each collection within the RDETB uses a standardised consent and collection approach to obtain material that would otherwise be destroyed or not retained. There is scope for prospective studies recruiting through the RDETB. Both collections have a steering committee controlling access, including lay members from within the biobank. There is a standardised approach for requests and the committee sits once a month. In addition, access to gifted samples within the PRB will involve contact with the PI, where possible. Some studies have additional steering committees where they have been carried out in consortia with other centres. First contact via this directory is encouraged, to establish your needs and our ability to meet them.
NIHR National Biosample Centre (UK Biocentre) Bedfordshire The NIHR National Biosample Centre is a not-for profit enterprise supporting NIHR funded researchers across the UK. Control and rights to all samples managed by us remains with the Investigator. We offer at scale storage and processing of bio-samples with the capacity for up to 20 million stored samples in automated storage systems. Additional capacity exists for managed freezer collections and vapour phase liquid nitrogen cryostorage. We provide automated DNA/RNA extraction/normalisation and quantification services as required.
NIHR Nottingham Digestive Diseases Collection Nottinghamshire The NIHR Nottingham Digestive Diseases Biomedical Research Unit (NDDBRU) has become the central hub to the gastroenterology and hepatology research within the partnership of University of Nottingham and Nottingham University Trust, bringing together 67 principal investigators bridging basic scientific and clinical fields. Among this large group, we have expertise in a wide range of areas, techniques and methodologies although we focus on early translational studies including pre-clinical and phase I/II studies. We host large deeply phenotyped cohort of patients, linked databases and biological samples. Our academic partnership extends to industry links and we do have experience in developing and evaluating, drugs, devices and health care interventions. NIHR NDDBRU has a mission to take the most promising basic biomedical research breakthroughs and translate them into patient benefit. We focus on developing novel tests, techniques as well as new treatments. We perform experimental medicine investigations into mechanisms underlying disease processes using biological samples from people; we evaluate the efficacy of interventions in volunteers and patients. Our research focus is on ’The infections, inflammation and consequences in the GI tract and liver’.
NIMRAD-TRANS Lancashire A retrospective sample collection of formalin fixed paraffin embedded (FFPE) pre-treatment diagnostic biopsies from patients with Head and Neck Squamous Cell carcinoma (HNSCC) enrolled on the NIMRAD trial.
Northern Ireland Biobank (NIB) Antrim Northern Ireland Biobank was established in 2010 to collect, store and distribute human samples for translational research and is primarily funded by the Northern Ireland Health and Social Care Research & Development Division of the Public Health Agency. Cancer Research UK (CR-UK), the Friends of the Cancer Centre and Prostate Cancer UK have also provided financial support. The NIB complies with approvals from both the Office of Research Ethics in Northern Ireland and HSC R&D governance to host and distribute cohorts of quality assured biological samples linked with well-defined clinical and pathological data sets.
Norwich Research Park Biorepository Norfolk The NRP Biorepository is a newly developing service facilitating world leading research on the Norwich Research park, home to institutes including Quadram Biosciences, the UEA, the Norfolk and Norwich University Hospital, John Innes and the Earlham Institute. Established and funded as part of the development programme of the Park, it supports academic and commercial researchers both locally and from outside the Park in all aspects of tissue based research.
Nostra feasibility trial West Midlands A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies
NRS Lothian Bioresource Midlothian The NRS Lothian Bioresource provides access to a wide range of characterised tissue collected in a healthcare setting for use in research. This includes surplus material from diagnostic specimens and surgical procedures. The Bioresource Lothian can facilitate collection of the following material: Pathology archive samples Surplus diagnostic samples - such as blood, urine or other bodily fluids Surplus diagnostic or surgical tissue Bespoke collections of tissue
Obesity Research Biobank Syndicate (ORBiS) Middlesex Bariatric surgery produces substantial, long-term weight loss with reduced morbidity and mortality. Genetics can strongly influence this response, as well as the initial propensity to obesity. Several genes have been implicated but more in-depth mechanistic studies are needed to understand how genes affect energy regulation and mediate the beneficial effects of bariatric surgery. The Obesity Research Biobank Syndicate (ORBiS) aims to fulfil this need. It provides a comprehensive collection of high-quality biological samples and patient data to facilitate mechanistic research and help translate it to improved treatments for patients. Patients undergoing bariatric surgery are recruited from multiple centres in the UK. With informed consent, blood or saliva samples are collected pre-operatively and tissue collected during surgery. Samples include: adipose tissue (subcutaneous and visceral), muscle, liver, stomach and small intestine. Relevant clinical and demographic data are linked and stored pseudoanonymised in a secure database. Tissue collections are transported to and processed in the ORBiS laboratory at University College London, and stored at UCL-Royal Free Hospital Biobank for future use. Research programmes will be supported within and beyond the contributing sites. External researchers will be required to obtain individual REC approval prior to submitting an application.
Oncology Clinical Trials Office, University of Oxford Oxfordshire OCTO was established in 2002 to run trials concerned with the practical application of high quality research into innovative and effective cancer therapies and prevention strategies. Our portfolio of trials includes a range of projects from first in human drug trials through to large Phase III clinical studies. Studies assess interventions including radiotherapy, drug combinations and novel imaging techniques. Tumour types include: colorectal, oesophageal, melanoma, lung, breast, cervical, haematology, and bone sarcoma, in both adjuvant and advanced disease.
Orchid Tissue Bank London The Orchid Research Tissue Bank is a Genito-Urinary tissue bank collecting and storing samples of prostate, testis, penile, kidney and bladder cancer. It consists of fresh frozen and formalin fixed tissue samples as well as whole blood, plasma and serum collected from patients with Genito-Urinary cancers or being investigated for malignancy. The bank was set up with the purpose of expanding the collection of male-specific cancers; providing material for scientific research aiming to discover new biomarkers that have the potential to be used as diagnostic/prognostic markers. Ultimately, this could assist in creating personalised treatments for patients. In addition to our own in-house research we have collaborations with groups within the UK, in the EU and USA.
Oxford Cell & Tissue Biobank Oxfordshire Biobank is located within the Oxford University Hospital NHS Foundation Trust HTA Human Application license no 11106. Retrieves tissue for transplantation and research from living and from deceased persons. Tissue retrieved for Research so far includes: Brain, Spinal Cord, Heart Valve, Eyes, Testicular, Ovarian. This Oxford Biobank service is expanding and will consider requests for retrieval of other cells and tissues
Oxford Musculoskeletal Biobank Oxfordshire The Oxford Musculoskeletal Biobank (OMB) is a resource of tissue and blood samples donated by patients for use in medical research (primarily musculoskeletal). The Biobank provides a simple and efficient way to collect and store samples according to regulatory requirements, and it ensures fair access to the samples. Samples will usually be used for research studies which may contribute to increasing the knowledge and understanding of musculoskeletal diseases in order to improve diagnosis and treatment, and ultimately patient care.
Oxford Radcliffe Biobank Oxfordshire The Oxford Radcliffe Biobank (ORB) holds a Human Tissue Authority (HTA) licence for storage of human material for research, licence number 12217. The Licence Holder is the University of Oxford and the Designated Individual (DI) is Dr Clare Verrill. The licence covers activities within Oxford, at the main site, the John Radcliffe Hospital, and at the satellite sites, Cowley Store, Churchill Hospital, Nuffield Orthopaedic Centre and Department of Pharmacology. ORB provides infrastructure to underpin biobank activities and delivers a portfolio of integrated services to users, from acquisition, storage and distribution of biospecimens, through to governance, ethical and regulatory cover. The biospecimens and associated information managed by ORB will be used for research studies that may contribute to increasing the knowledge and understanding of disease in order to improve diagnosis and treatment, and could ultimately lead to improvements in patient care. ORB was established in 2006 when a number of active and legacy collections within the University of Oxford and the Oxford University Hospitals NHS Trust were brought together for licensing by the Human Tissue Authority (HTA). This was in response to new legislation, the Human Tissue Act (2004), which came into effect on 1 September 2006. ORB acts as a single gateway for access to the many biospecimen collections held in Oxford. Custodians of collections engage with ORB as part of a federated model. A primary focus of ORB is maintenance of a generic, open-access resource of biospecimens donated by patients and research participants for use in medical research and provision of a simple and efficient system to collect, store, curate, and distribute these biospecimens and associated information. In response to the requirements of the Human Tissue Act, ORB operates a multi-site Human Tissue Authority Research Licence with policies and procedures in place to ensure registered collections comply with the legislation. ORB also provides storage facilities according to HTA guidelines. It is recognised that access to large numbers of high-quality, clinically annotated biomaterials is vital for the advancement of medical research and healthcare delivery. ORB facilitates this access and enhances the research infrastructure by working with all stakeholders to ensure effective sharing of information, resources and best practice.
Pancreatic Cancer Research Fund Tissue Bank Middlesex The Pancreatic Cancer Research Fund Tissue Bank is the world's first national pancreas tissue bank and will accelerate research into pancreatic cancer. The Tissue Bank is funded by the medical research charity Pancreatic Cancer Research Fund, and is a unique collaboration between the charity, Barts Cancer Institute, Queen Mary University of London and six key NHS partners throughout the UK, each renowned for its expertise in treating pancreatic cancer
Partner Trial Cambridgeshire Randomised, phase II/III, 3-stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with triple negative and/or gBRCA sub-type.
Penile TPF Middlesex A Phase II non-randomised multicentre trial of docetaxel, cisplatin & 5-fluorouracil chemotherapy (TPF) in locally advanced and metastatic carcinoma of the penis. 26 evaluable patients recruited to receive Docetaxel 75mg/m2 day 1, cisplatin 60mg/m2 day 1, 5-fluorouracil 750mg/m2/day (day 1-5), peated at intervals of 21 days. The primary endpoint, measured by RECIST v1, (complete remission rate + partial remission rate). Secondary endpoints are te proportion of patients with inoperable locoregional disease rendered operable by TPF chemotherapy, progression-free survival, overall survival, acute toxicity (as determined by CTCAE) after each cycle and at 3 months and late toxicity (CTCAE). Formalin fixed paraffin embedded tissue samples are held at the Orchid Research Tissue Bank at Barts and the London School of Medicine and Dentistry.
PHOENIX DDR-Anti-PD-L1 Trial Surrey PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer
PHOTO Translational bladder cancer biorepository Tyne and Wear Translational study associated with the PHOTO trial - A pragmatic randomised controlled phase III trial, investigating the efficacy transurethral resection of bladder tumour (TURBT) using photo-dynamic diagnosis (PDD) under blue light in intermediate and high risk non-muscle invasive bladder cancer (NMIBC). The translational study is establishing a well-characterised cohort of patients with intermediate and high-risk NMIBC including clinical data, urine, blood and tumour specimens that would be available for separately funded research of genotypic and phenotypic studies
plasmaMATCH Surrey The UK plasma based Molecular profiling of Advanced breast cancer to inform Therapeutic Choices (plasmaMATCH) Trial: A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening
Plastic and Reconstructive Surgery Skin and Tissue Bank Lancashire The Plastic and Reconstructive Surgery Skin and Tissue Bank collects samples related to a range of skin and tissue clinical conditions including normal and abnormal skin scarring, dudpuytrens disease and breast capsules.
POETIC: Trial of perioperative endocrine therapy – individualising care Surrey Primary aim: To determine whether two weeks perioperative aromatase inhibitor (AI) therapy before and after surgery improves outcome compared with standard adjuvant therapy. Eligibility: Postmenopausal women with ER/PgR positive invasive breast cancer. Trial design: Phase III, multicentre, randomised trial Target accrual: 4350 patients Patients will be allocated in a 2:1 ratio to PERIOPERATIVE THERAPY with an AI for 4 weeks (two weeks before and two weeks after surgery) or NO PERIOPERATIVE THERAPY. Group I: PERIOPERATIVE THERAPY with an AI Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day) Group II: NO PERIOPERATIVE THERAPY 4 weeks (two weeks before and two weeks after surgery)
PORT Trial London Skin biopsies will be obtained from patients for translational studies to identify biomarkers of immunological response to the combination of pembrolizumab and radiotherapy in patients with advanced Cutaneous T Cell Lymphoma (CTCL).
POUT-T Warwickshire POUT-T: The translational substudy of a phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer. The objectives of POUT-T are: to investigate the molecular pathogenesis of Upper Tract Urothelial Carcinoma (UTUC); to identify prognostic and predictive biomarkers of UTUC; and to identify diagnostic biomarkers of UTUC. POUT-T participants are requested to provide the following specimens pre-operatively, post operatively, 6 months following surgery, and at disease recurrence: whole blood for germline DNA analysis; whole blood for cell-free DNA analysis; first moning urine for DNA, proteome and metabolome analyses. In addition, paraffin-embedded tumour tissue from nephro-ureterectomy is requested for immunohistochemistry and DNA/RNA analyses.
PTCL Biobank Leicestershire An Observational Study of Peripheral T cell Lymphoma: Establishment of a Biobank and Database. The outcome of this study will be a biobank of PTCL cases with linked clinical data and serum, saliva and plasma samples to enable assessments of treatment response and prediction of relapse.
Public Health England Seroepidemiology Unit Lancashire The basis of the PHE (formerly the Health Protection Agency) Seroepidemiology Programme is a large collection of sera representative of the general population of England, forming a unique and valuable public health resource. The collection is stored and maintained by the Seroepidemiology Unit (SEU) at the Public Health Laboratory (PHL), Manchester. Sera submitted to the SEU are residues of specimens submitted for diagnostic testing. They sample the population range and are anonymised prior to archiving (retaining age, sex, date of collection and source laboratory only). Collection of sera is continuing through collaboration with the PHE Microbiology Services Division (MSD) and some NHS laboratories throughout England, and has occurred annually since 1986. Over 230,000 sera are now stored and catalogued. The collection can be made available for testing to anyone wishing to use it to address issues related to public health policy.
QTL Programme at MRC HGU Midlothian The QTL (Quantitative Trait Locus) programme is based at the MRC Human Genetics Unit in the University of Edinburgh. The research programme uses the unique population structures in our Scottish and Croatian cohorts to deliver biological understanding of the causes of variation in complex traits. Together, the ORCADES and VIKING biobanks contain 4,000 samples from volunteers with ancestry from the Northern Isles of Scotland, www.ed.ac.uk/viking. Collectively, the CROATIA cohorts contain 6,000 participants. All of these biobanks were constructed from people with high kinship and extensive pedigree structures. They were collected together with detailed phenotype data, some of which is longitudinal. Plasma, serum, urine and DNA samples, as well as detailed genomic, proteomic and metabolomics data can be made available for collaborative research.
Queen Mary University of London London Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting, conducted by the Transatlantic Prostate Group (TAPG) is a long-term retrospective epidemiology cohort study on factors predicting clinical progression of prostate cancer. The TAPG study started in 1999 and comprises approximately 3,300 men diagnosed with prostate cancer between 1990 and 2006. This exploratory study aims to identify prognostic markers that will more accurately predict the probability of recurrence and allow for better patient selection for radical treatment of prostate cancer.
QUOD - Quality in Organ Donation Oxfordshire Organ donation and transplant saves thousands of lives a year and could be considered one of the greatest successes in modern medicine. However, over the past decade, there has been an ever increasing need for organs throughout the UK, far surpassing the supply. This is a pattern that is predicted to worsen over the next 10 years. As many as one in three patients on the transplant waiting list will die or become too unwell to receive a transplant as a result of this disparity. To address this problem, the transplant community have been turning to organs previously considered to be unsuitable for transplantation, including organs from extended criteria donors and non-heart beating donors. In order to do this, QUOD aims to facilitate research by collecting blood, urine and tissue samples of appropriately consented / authorised organ donors. Through this, it may be possible to determine pathways of injury and repair in organs and identify biomarkers which can be used to better predict the outcomes of transplantation. QUOD is a nationwide programme encompassing all retrieval zones in the UK. These regions include: •Birmingham / Cardiff •Cambridge •Edinburgh •London Kings •Manchester / Leeds •Newcastle •Oxford / Royal Free The QUOD team has a wide range of personnel, including specialist nurses, transplant surgeons, academics, management teams and a variety of healthcare professionals. The samples collected throughout the QUOD programme are available for research purposes. Samples will be available to research projects based on scientific merit. More information about the access policy can be found on the website.
RAPPER Lancashire RAPPER (Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy) is a national radiogenomics study investigating the association between common genetic variation determined by single nucleotide polymorphisms (SNPs) and radiation toxicity.
RATHL Trial London RATHL is a multicentre, randomised, phase III trial comparing treatment outcome for patients with advanced Hodgkin lymphoma, using FDG-PET imaging after 2 cycles of ABVD to determine response and subsequent management. Recruitment target: 1200 patients Patients received 2 cycles of ABVD and then had a PET-CT scan. PET negative patients were randomised to either ABVD or AVD for a further 4 cycles. PET positive patients received either BEACOPP-14, for 4-6 cycles or BEACOPP escalated, for 3-4 cycles. Samples collected for trial: Formalin fixed paraffin embedded tumour block - sent to HMDS, Leeds. Blood sample to be analysed at site. Blood sample - sent to Simpson Centre for Reproductive Health, Edinburgh.
RE-AKT Surrey A multicentre prospective, randomised, phase II interventional study in mCRPC patients previously treated with 1-2 lines of chemotherapy and at least 12 weeks of abiraterone with a safety run-in and single stage phase II expansion cohort
REPROCELL Europe Ltd Glasgow (City of) REPROCELL Europe Ltd is a Contract Research Organisation specialising in the use of fresh human tissues to better predict drug efficacy and safety during non-clinical drug development. We source a range of fresh healthy and diseased tissues from multiple providers, across the UK, Europe and the USA, for specific academic and pharmaceutical industry sponsored projects conducted within REPROCELL facilities. Services utilising fresh tissue include pharmacological assays, 3-D culture and induced pluripotent stem cell production using our exclusive RNA re-programming technology. Through our REPROCELL partner group we also have access to a global biorepository of human serum, DNA, RNA and FFPE samples.
REQUITE Lancashire Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors. The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy. Funded by the European Commission FP7 HEALTH scheme.
Respiratory Tissue Archive Hampshire This is a collection of bronchial and nasal biopsies collected between 1989 and February 2006 from volunteers with asthma, COPD and rhinitis, and age matched controls as part of the University of Southampton's ongoing respiratory research programme.
RIO Surrey Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
RJAH Biobank for Studying Health and Disease Shropshire Orthopaedic tissues Wax embedded and fresh frozen tissues of primary and secondary bone tumour and metastatic disease. If a certain tissue types are required with the correct Ethics and consent in place these could be collected and stored at the tissue bank.
Royal Papworth Hospital Research Tissue Bank Cambridgeshire We collect all tissue arising from cardio-thoracic procedures, including, but not limited to: aorta, myocardium, heart valves, cardiac and peripheral vessels, lung, airways, blood vessels pulmonary,blood, sputum and tumour samples. We also provide relevant routine clinical data such as previous medical history and certain treatment details.
RxCelerate research biobank Cambridgeshire Plasma and serum samples from patients with atherosclerosis and assumed healthy controls
Scleroderma and Raynaud's Research Bank Greater Manchester The Scleroderma and Raynaud's Research Bank (SRRB) consists of a Bank of blood, DNA, serum, skin biopsies, calcinosis samples and capillaroscopy and thermography images with associated clinical data. These are collected on patients with scleroderma (both systemic sclerosis spectrum disorders including localised scleroderma also termed morphoea), patients with other connective tissue diseases, patients with primary Raynaud’s phenomenon, patients with shoulder problems leading to deposition of calcium salts (deposition of calcium salts also occurs in scleroderma) and healthy controls. The Bank currently contains samples from over 800 individuals, collected as part of individual research projects and the ongoing assessment of patients attending general rheumatology, scleroderma and dermatology clinics acting as tissue collection centres.
SCOT translational sample collection Glasgow (City of) The SCOT study enrolled more than 6000 patients over a 5 year period and is the largest single trial ever conducted in CRC. Tissues collected from patients entered in to the study are physically hosted in two sites; blood samples and blood fractions e.g. DNA, are held at the University of Oxford and FFPE samples are housed at the Glasgow Biobank. There are approximately 3000 blood and 3000 tissue samples in the collection. The associated clinical data is held by the Cancer Research UK Clinical Trials Unit, Glasgow.
Scottish Early Rheumatoid Arthritis (SERA) Glasgow (City of) The Scottish Early Rheumatoid Arthritis (SERA) study is an inception cohort of rheumatoid (RA) and undifferentiated arthritis (UA) patients that aims to provide a contemporary description of phenotype and outcome and facilitate discovery of phenotypic and prognostic biomarkers.
Scottish Human Papillomavirus Archive Midlothian The Scottish HPV Archive is a biorepository of samples that provides a vital resource for researchers to improve the way we detect and manage HPV associated disease. The archive is housed within the Queen's Medical Research Institute, University of Edinburgh, and follows the governance policies of NHS Lothian for tissue collections and the bio-repository principles of the Lothian NRS Bioresource (SAHSC). It currently holds over 40,000 samples, the majority of which are cervical liquid-based cytology (LBC) samples although derivatives thereof (including nucleic acid) and other anogenital sample types are also available. For most of the samples, aliquots are kept at different temperatures (-80˚C or -25˚C) and different volumes (original sample and concentrated aliquot). The key attribute of the Scottish HPV archive is the annotation of samples with HPV and vaccination status as well as pathology information. Such linkage is possible in Scotland with the help of the Community Health Index (CHI), Scottish Cervical Call and Recall System (SCCRS) and Cancer Registry.
Sheffield Brain Tissue Bank (SBTB) South Yorkshire Sheffield Brain bank comprises of tissue samples mainly of Degenerative diseases (MND, Alzhiemers)
Sheffield Collaborating Centre of the Breast Cancer Now Tissue Bank South Yorkshire The University of Sheffield collects malignant and normal breast tissue and blood samples from patients attending the Royal Hallamshire Hospital and Weston Park Hospital, Sheffield as part of a research project led by Prof. Angela Cox; "The role of angiogenesis and genome stability in breast cancer, and biosample collection". The research group specialises in the collection of longitudinal blood samples, including blood plasma for circulating DNA applications. Patients are invited to donate their samples to the Breast Cancer Now Tissue Bank (BCNTB), a ground-breaking, multi-million pound initiative linking five centres around the country which work together as one national resource. The BCNTB represents the UK’s single largest unique collection of high-quality breast tissue samples. Breast Cancer Now Tissue Bank samples are held in the Leeds Breast Research Tissue Bank at St. James University Hospital, a founder member of the BCNTB.
Sheffield Lung Research Tissue Bank South Yorkshire This lung tissue research bank at the University of Sheffield supports a long-standing interest in lung cell biology. Projects have investigated aspects of lung mast cell and macrophage biology and current work is focussed on pulmonary vascular cell biology. As part of this ongoing research we have curated more than 1000 samples of ‘grossly normal’ lung tissue from individuals who have undergone lung surgery.
Sheffield Pulmonary Hypertension Biobank South Yorkshire Longitudinal collection of blood samples from patients with pulmonary hypertension and associated lung and cardiovascular disease, as well as some healthy volunteers as controls. The biobank samples with associated clinical data are used in research into the these conditions, how they cause symptoms and illness, and to develop new ways to diagnose, treat, and prevent diseases.
SHiMR (Sheffield Hospitals Myeloid Research) South Yorkshire Our aim is to facilitate access to tissue samples for basic and translational research that investigates the causes, complications and therapy of myeloid blood disorders, with the ultimate aim of improving treatment for patients with these disorders. We are generating a collection comprising prospective collection of blood and bone marrow samples, access to material surplus to requirements for clinical care, and linked summaries of relevant clinical information. All samples are obtained with written informed consent from donors. The collection will include cryopreserved material suitable for in vitro and in vivo research. To request sample access please contact us for an application form, which will be reviewed by the SHiMR management committee.
South Yorkshire and North Derbyshire Musculoskeletal Bio Bank South Yorkshire The SYNDMB collects, stores and distributes tissue samples as necessary to deliver tissue to approved research projects. This may include the collection of samples from donors with rare conditions or characteristics of special interest for use in future research that is not yet defined. The SYNDMB may accept a wide range of samples and data obtained from donors, or completed, ethically approved projects with appropriate consent for Biobank storage, in South Yorkshire and North Derbyshire, elsewhere in the UK and internationally (including countries outside the EEA)
St Thomas' Hospitals Plasma, serum & DNA Bio bank from patients with antiphospholipid antibodies Surrey A frozen biobank collection of plasma, serum, and DNA from APS patients. Each sample is anonymised blood sample collected from patients who consent for its use in future research into Antiphospholipid Syndrome. APS is defined as the association of antiphospholipid antbodies (aPL) with arterial or venous thrombosis and /or pregnancy morbity. Antiphospholipid syndrome is an autoimmune disorder in which aPL are involved in the development of venous and/or arterial thrombosis.
STAMPEDE Middlesex tbc
SUN Study Surrey The SUN study is a Bio repository of 6 monthly sequential blood samples from 350 men with Prostate Cancer - pre-treatment and through follow-up
SWIFT-RTB Cardiff Fetal tissue
Tayside Biorepository Angus Tayside Biorepository is an established bio-resource responsible for the provision of a wide range of human tissue from consenting patients in addition to providing a large range services including staining and extraction methods.
The Airwave Health Monitoring Tissue Bank Middlesex The Airwave Health Monitoring Study was established to evaluate possible health risks associated with the use of TETRA, a digital communication system used by the police forces and other emergency services. It is a long-term observational study following up the health of police officers and staff across Great Britain, with the ability to monitor both cancer and non-cancer health outcomes. Around 53,000 participants have been recruited between June 2004 and March 2015 with a response rate averaging 50% of employees in participating forces. At baseline, participants completed an enrollment questionnaire (sent via routine administration or the occupational health service), or a comprehensive health screening performed locally, or both. Around 85% (N=45,000) of the sample received a health screening. Clinical and biological measurements were taken, blood and urine samples collected. Participants were 40 years old on average (between 17 and 80 years old at inclusion), mostly men (63%) and white British (85%). Participants have now been followed-up for 7.5 years on average. A second assessment of participants living in England started in November 2015 and is ongoing.
The Cleft Collective Avon The Cleft Collective is a longitudinal cohort study looking to investigate the biological and environmental causes of cleft and the best treatments of cleft on those affected and their families. The study comprises two separate cohorts, a Birth Cohort and a 5-year-old Cohort. The birth cohort is further split into two sub-groups, postnatal and antenatal, allocation to these groups is determined by the time of recruitment. Recruitment to the two cohorts is currently ongoing across the UK. A large amount of phenotypic and environmental exposure data is being collected via questionnaires and record linkage. A data dictionary, available on the study website, contains details of all the available data. As a minimum, biological mother and affected child are recruited to the study. Where possible, biological father or mother’s partner is also recruited. In addition, the study aims to recruit unaffected and affected siblings for a small proportion of the cohort. Biological samples are collected from all participants. Parents and siblings of both cohorts and affected children of the 5-year-old cohort provide saliva samples. Residual tissue and blood samples are collected from affected children recruited to the birth cohort. In addition, cord blood samples are collected from families recruited to the antenatal strand.
The PEACE Study Middlesex The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
The Swansea Neurology Biobank Cardiff The Swansea Neurology Biobank, (SNB) is a collaboration between Swansea University and Local Health Boards, collecting biological specimens from a range of neurological phenotypes.
Tissue Access for Patient Benefit (TAPb) Middlesex We aim to facilitate the pathway for access, storage, use and transfer of human organs, cells and tissue between clinical centres within UCL Partners, academic groups in UCL, other universities, hospitals, medical researcher and biotechnology companies, to enhance the ability for researchers to access the materials they need. Alongside this, researcher will be able to exchange information and access guides on regulatory, ethics and practical issues concerning access, transfer and use of this type of material. These guides will be video and documents format, based on talks at organised events given by experts in the relevant fields.
Tissue Solutions Ltd Glasgow (City of) Tissue Solutions specializes in sourcing biological material for academics, pharma & biotech companies and CROs and is working with clients worldwide (USA, UK, Europe and Japan). We are a virtual tissue bank, working with multiple sources to acquire samples on behalf of our clients for use mainly during the preclinical research phase. We never retain tissues ourselves for our own use. We provide access to banked human tissues and set up prospective collections in the UK and USA. We specialise in sourcing "tough" tissues, eg fresh samples or those with specific inclusion and exclusion criteria. We provide both diseased and non-diseased samples, FFPE and fresh frozen and fresh samples.
TNT: Triple Negative breast cancer Trial Surrey TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 wks) Group B: Docetaxel 100mg/m2, q 3 weeks for 6 cycles (18 wks) On evidence of disease progression, patients will cross over to the alternative treatment.
Tommy's National Reproductive Health Biobank West Midlands The Tommy's Biobank aims to prospectively collect samples from pregnant and non pregnant women to help research in to pregnancy complications. The biobank has been granted permission to ethically approve research projects conducted in the field of reproductive health. The biobank will bring together six biobanks that will all collect samples of high quality according to the standard operating procedures written by experts in the field of reproductive health.
TOPARP: Ph. II Trial of Olaparib in Patients with advanced CRPC Surrey TOPARP is an open-label, single arm, two part adaptive design phase II trial of olaparib in mCRPC. Patients will receive single agent olaparib at a dose of 400 mg twice daily, continuously on a 28-day cycle, until objective disease progression or unacceptable toxicity or patient withdrawal for whatever reason.
TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy (Rx)) London A prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study.
TRICON8 Cambridgeshire TRICON8 is the translational research sub-study of the ICON8 trial. Its aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8 is a phase III randomised controlled trial designed to investigate the safety and efficacy of two dose-dense, dose-fractionated, weekly carboplatin-paclitaxel combination chemotherapy regimens for the treatment of newly diagnosed ovarian cancer compared to standard three-weekly carboplatin-paclitaxel. There is a growing body of evidence that using dose-fractionated paclitaxel in particular may have increased anti-tumour effects, and this is thought to be due to enhanced anti-angiogenic and pro-apoptotic effects.
TRICON8B Cambridgeshire TRICON8B is the translational research sub-study of the ICON8B trial. The aim is to establish a large, comprehensive biobank comprising tumour tissue, blood and serial plasma samples with associated clinical data which will be an invaluable resource for high-quality translational research in ovarian cancer. ICON8B is a phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer.
TwinsUK London The TwinsUK cohort, set up in 1992, is a major volunteer-based genomic epidemiology resource with longitudinal deep genomic and phenomic data from over 14,500 adult twins (18+) who are highly engaged and recallable. It is one of the most deeply characterised adult twin cohort in the world, providing a rich platform for scientists to research health and ageing longitudinally. More than 800 data access collaborations and 150,000 samples have been shared with external researchers, resulting in ~600 publications since 2012. There are over 500,000 biological samples stored and data collected on twins with repeat measures at multiple timepoints.
UCL / UCLH Biobank for Studying Health and Disease Middlesex The Biobank stores normal and pathological specimens, surplus to diagnostic requirements, from relevant tissues and bodily fluids. Stored tissues include; snap-frozen or cryopreserved tissue, formalin-fixed tissue, paraffin-embedded tissues, and slides prepared for histological examination. Tissues include resection specimens obtained surgically or by needle core biopsy. Bodily fluids include; whole blood, serum, plasma, urine, cerebrospinal fluid, milk, saliva and buccal smears and cytological specimens such as sputum and cervical smears. Fine needle aspirates obtained from tissues and bodily cavities (eg. pleura and peritoneum) are also collected. Where appropriate the Biobank also stores separated cells, protein, DNA and RNA isolated from collected tissues and bodily fluids described above. Some of the tissue and aspirated samples are stored as part of the diagnostic archive.
UCL BioResource London The UCL BioResource is a genetics research registry that obtains samples as well as basic demographic and phenotypic details on patients and healthy volunteers. The majority of participants are also genotyped. This facilitates recall of volunteers, use of samples, or use of data based on phenotypic and/or genotypic criteria.
UCL Eastman Biobank Middlesex The UCL Eastman Biobank will act as a physical repository for collections of biological samples and data for research purposes from consented patients at the Eastman Dental Institute and Hospital, University College London and University College London Hospitals Foundation Trust (Eastman). This will incorporate prospective collections of stored samples and new collections. It provides a unique opportunity to advance dental and medical research by making access to tissue surplus to requirements easier, and more efficiently, and with a high level of governance compliant with HTA standards. The Biobank will support projects principally involved in the study of human disease and the normal functioning of the human body. The Biobank will store normal and pathological specimens from relevant tissues and bodily fluids. Tissue will be stored in a variety of formats. The establishment of a core programme will enable a centralised approach to the management and integration of all research groups working within these institutions, providing appropriate structure and support.
UCL Infection DNA Bank Middlesex The UCL Infection DNA Bank aims to facilitate research into infectious diseases through the enhanced availability of samples to researchers. This availability currently supports research in the UCL Division of Infection and Immunity but it will also support researchers nationally and internationally, increasing the potential for collaboration.
UCL Royal Free Hospital Biobank Middlesex The physical repository was established in Nov 2009 and is located within the Royal Free London NHS Trust, London UK. The UCL-RFH Biobank provides a biorepository facility to user groups on a cost-recovery model. Types of biospecimens include Serum, Plasma, Cells, Tissue, DNA, Urine etc. In particular, samples considered 'relevant material', such as tissues and cells, which are licensed by the Human Tissue Authority (HTA), can be stored long term. Existing holdings where appropriate can be transferred to the BioBank at the Royal Free Campus. The physical repository has a planned onsite capacity of 1 million samples. Samples can be stored at -80’C in mechanical freezers or -180’C in vapour phase liquid nitrogen, in either 1ml or 2ml cryotubes. The Biobank is licenced by the HTA (substantive licence No. 11016) and is a satellite site of the clinical transplant laboratory (Centre for Cell, Gene and Tissue Therapeutics) based at the Royal Free Hospital. Over the past 5 years, the demand for the biobank’s facility has increase exponentially, increasing between 50%-100% year on year. The biobank currently provides biorepository facilities to 46 user groups who collectively have stored 200,000 aliquots.
UK Biobank Cheshire UK Biobank is a major national health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.
UK CLL Trials Biobank Lancashire A collection of Chronic Lymphocytic Leukaemia samples from patients on clinical trials. Includes the trials; AdMIRE, ARCTIC, CHOP-OR, CLL210, CLEAR, COSMIC, RIAltO, FLAIR
UK ME/CFS Biobank London Participants: Over 650 participants are included in the study, including ME/CFS participants diagnosed by a physician and compliant with CDC ’94 (Fukuda) and Canadian Consensus Criteria (CCC), with case definition compliance available for four other commonly-used criteria. Healthy and MS matched controls are also available. • Mild and Moderate ME/CFS • Severe (Home-Bound) ME/CFS • Multiple Sclerosis • Healthy Controls Samples Available: Over 32,000 aliquots available. • Whole Blood • Serum • Plasma • RBCs • PBMCs (Sodium Heparin and K2 EDTA) • Blood for RNA Extraction (PaxGENE) Associated Data Available: • Baseline Standard Laboratory Tests to exclude comorbidity causes of fatigue • In-person clinical assessment data • Detailed Symptoms Assessments • Demographic information • Standardised instruments of Fatigue Severity and Functional Impairment
UK MND Collections Northamptonshire The UK MND Collections (formerly known as the UK MND DNA Bank) was established to provide the international research community with a resource that would help to identify and understand the causative and disease modifying factors involved with motor neurone disease. These samples are available for research into MND and associated conditions such as fronto-temporal dementia only. The UK MND Collections combines more than 3,000 biological samples and accompanying clinical information; as well as epidemiology data from 400 participants, including people with MND, controls and family members. The DNA Bank was the original Collection of whole genome DNA from over 3,000 blood samples, which are stored at CIGMR (Centre for Integrated Genomic Medical Research) in Manchester, UK. The DNA Bank also has clinical information (divided into a minimum and extended dataset) which is available to researchers. The Cell Lines Collection offers a sub set of the DNA Bank samples as EBV-transformed lymphoblastoid cell lines and peripheral blood lymphocytes. This was originally set up as an everlasting supply of DNA, with the lymphoblastoid cell lines now available to researchers to help them understand how the disease is developing. The Epidemiology Collection has just over 200 patient and matched control blood samples with extensive environmental and lifestyle data (both from self-report questionnaires and telephone interviews) available to researchers. More information on the DNA and cell bank is available in Smith et al BMC Genetics (2015) 16:84.
UK primary Sjogren's syndrome Registry Northumberland Peripheral blood samples (DNA, RNA, serum, PBMC) from patients with primary Sjogren's syndrome, with detailed contemporaneous clinical data at the time of sample collection.
UK real-world lymphoid tissue bank Hampshire The UK real-world lymphoid malignancies tissue Bank (UKTB) provides a national and international resource for research on lymphomas and other lymphoproliferative disorders including chronic lymphocytic leukamia. This Research Tissue Bank was set up in 2014 and given favourable ethical opinion (REC ref: 14/SC/0030). The samples are stored in the HTA licenced Faculty of Medicine Tissue Bank. The RTB currently holds matched normal and malignant frozen material from ~900 patients. The samples collected can be associated with clinical diagnostic details and outcome endpoint, which can be readily informative to patient prognosis.
UKALL14 Trial London A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia. Multisite, randomised controlled trial, recruiting 811 patients over 7.5 years. Samples will be collected throughout the trial and sent to the central lab (Adult ALL MRD Lab @ UCL CI) as follows; - bone marrow samples taken at diagnosis, at recover post phase 1 and phase 2, post transplant (for those patients who proceed with a non-myeloblative transplant) and at relapse. - pheripheral blood sample taken during phase 1 on days 4 & 18 (in patients 40 and under) and on D18 & 32 in patients 41 or over), and during intensification. Additionally for those patients who proceed for a non-myeloblative transplant peripheral blood will be sent to the local chimerism labs and a copy of the report will be sent to UCL CTC.
Ukall60 Trial London The UKALL60+ trial is a multi-centre, prospective, non-randomised, multiple pathway trial to document the safety, tolerability and efficacy of standard ‘backbone’ chemotherapeutic regimens in older patients with de novo ALL. Samples will be collected throughout the trial and sent to the central lab (Adult MRD lab at UCL CI) as follow: 1. At diagnosis (pre trial registration) 2. After Phase 1 Induction 3. After Phase 2 Induction 4. a) After Intensification (for patients on the pathway B ONLY) b) After Consolidation 1 (Pathways A, C & D) An additional bone marrow or peripheral blood sample is also sent to the MRD lab if the patient relapses. This sample should be from the routine sample taken to diagnose relapse.
UKCTOCS Longitudinal Women's Cohort (UKLWC) London This is the bioresource resulting from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), one of the world’s largest randomised controlled trials. Between 2001-2005 1.2 million women aged 50-74 years were invited from the general population and 202,638 post-menopausal were randomised (2:1:1) to routine care, or annual CA125 blood testing (7-11 rounds) or ultrasound to evaluate the impact of ovarian cancer screening on disease mortality. All participants provided a serum sample at recruitment with 50,262 providing further longitudinal annual samples (median of 9 samples). Women were free of any active malignancy at enrolment (2001-2005). During the follow-up period of >15 years to-date a proportion of those have subsequently developed a number of different diseases. Available comprehensive electronic health record linkage of the cohort’s participants (including Hospital Episode Statistics (HES); ONS (Cancer registry, Death Certificates); National Cancer Intelligence Network (NCIN); and Myocardial Ischaemia National Audit Project (MINAP) allows exploiting clinical phenotyping and diseases diagnoses made during routine healthcare in the NHS. Women were also sent postal questionnaires. Secondary studies have to date generated additional data on symptoms, menopause and its management and further details of individual cancers. The biobank contains >540,000 high-quality serum samples (10 x 500μL aliquots in straws), composed of baseline (from >189,000 women) and a unique longitudinal set of >350,000 annual serial samples (median 9) (from approximately 50,200 women). Samples have already been validated for multi-omics analysis with academic and commercial collaborators in nested case/controls sets used for genotyping, proteomics (including SWATH technology), methylation, NMR metabolomics, autoantibody profiling, ELISA-based assays, lipidomics and miRNA. All data is stored in the IG Toolkit-compliant and ISO 27001:2013-certified UCL Data Safe Haven. All samples from the biobank have been collected using a standardised protocol and stored in liquid nitrogen at HTA licensed facilities at UK Biocentre, Oxford, UK.
UNIRAD UK Sample collection Surrey Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease (UNIRAD).
University of Leeds West Yorkshire Samples collected from patients in the CALIBER trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer
University of Leicester Cancer Research Biobank Leicestershire The Biobank collects and stores samples for local studies. Samples collected include; •Frozen disease-affected tissue •Paraffin embedded disease-affected tissue •Blood •Urine •sorted stem cells
University of Liverpool - GCP Laboratory Facility Lancashire Combined repository of clinical trial samples for ‘future use’. Will include samples from clinical trials co-ordinated by the Liverpool Cancer Trials Unit and from studies with Liverpool Principal Investigators.
University of Sheffield South Yorkshire Longitudinal blood samples from patients with suspected and confirmed pulmonary hypertension
University of Southampton Faculty of Medicine Tissue Bank Hampshire The Tissue Bank is licensed by the Human Tissue Authority (HTA) to source, organise, collect, prepare, store and distribute a diverse collection of human tissues and biological products. All tissue is collected with patient consent and distributed anonymously only to National Research Ethics Service (NRES) approved studies. This valuable resource is available to aid the study of cancer biology and other associated research. The Tissue Bank allows for rapid access to a plethora of biological materials supported by an inventory management system. Tissues currently available include normal and malignant snap frozen tissue, FFPE blocks, fresh biopsy tissues, blood products and biological fluids. Collections are organized by Tissue Bank staff and include a wide variety of cancer classifications. The Tissue Bank currently holds over 100,000 vials.
VinCaP Middlesex VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoints are objective response rate (CR+PR), toxicity, progression-free survival, overall survival and treatment compliance. Formalin fixed paraffin embedded (FFPE) tumour blocks are held at the Orchid Tissue Laboratory and Barts and The London School of Medicine and Dentistry.
VORTEX-BIOBANK Lancashire Collection of matched tumour and normal tissue samples, FFPE blocks and EDTA blood samples from human soft tissue sarcoma (STS).
Wales Cancer Bank Cardiff The Wales Cancer Bank (WCB) was set up in 2004 and consented the first patient in 2005. The project is hosted by Cardiff University and receives funding from the Welsh Government, Cancer Research Wales and Velindre Charitable funds. A Cancer Bank is literally a collection of tissue and blood which has been collected from patients where cancer is a possible diagnosis and is being stored to facilitate future research into cancer. Statistics suggest that four out of ten people will be diagnosed with cancer at some point during their life. Cancers are complex diseases and it is an on-going quest to understand how they develop, spread and can be treated. The development of more effective, targeted treatment for cancer depends on increased understanding of the molecular mechanisms involved in the initiation of the tumour, its progression to metastatic disease and response and resistance to treatment. Research studies rely on the availability of high quality biological material from patients with cancer and large studies are needed to correlate biology with clinical outcome. The Welsh population is relatively stable and this makes it an ideal cohort to collect and study. Linkage with the all Wales cancer clinical database (CANISC) enables good correlation of science with clinical follow-up. This will eventually enable the results from hundreds of research projects to be integrated and linked to clinical outcome and this will be an invaluable source of data for bioinformatics specialists to examine. All the data collected is being stored on a database housed in the NHS to ensure security and confidentiality The WCB currently consents patients in 12 hospitals around Wales with specially trained research nurses and clinical teams.
Watch and Wait Trial London Watch and Wait is a randomised phase III trial to determine whether initial treatment with rituximab in patients with advanced stage asymptomatic follicular lymphoma (grades 1, 2 and 3a) results in a significant delay in the initiation of chemotherapy or radiotherapy and the impact of each strategy on patient-related quality of life. 360 patients randomised to receive either Rituximab treatment and maintenance or to a Watch and Wait strategy. Samples collected for trial: Formalin fixed paraffin embedded tumour block or unstained slides (lymph node and bone marrow)- sent to HMDS. Blood and bone marrow sample taken at baseline and if patient in CR clinically and radiologically at 7, 13 and 25 months - sent to University College London Hospital
York Tissue Bank North Yorkshire In collaboration with York Teaching Hospital NHS Trust, the University of York has established the York Tissue Bank: a tissue bank to help research into human disease. We aim to collect, store and build a repository of human tissue samples, such as urine, blood and tumours. These can then be given to researchers for their studies. These studies will aim to improve our understanding of human health and potentially lead to new methods of diagnosis, better treatments and vaccines for a wide range of diseases. We rely on participants to voluntarily gift their tissue samples for this vital future research. Our Bioresource is described in detail here: https://openbioresources.metajnl.com/articles/10.5334/ojb.49/